



HAL
open science

A neutralizing antibody prevents post-fusion transition of measles virus fusion protein

Dawid Zyla, Roberta Della Marca, Gele Niemeyer, Gillian Zipursky, Kyle Stearns, Cameron Leedale, Elizabeth Sobolik, Heather Callaway, Chitra Hariharan, Weiwei Peng, et al.

► **To cite this version:**

Dawid Zyla, Roberta Della Marca, Gele Niemeyer, Gillian Zipursky, Kyle Stearns, et al.. A neutralizing antibody prevents post-fusion transition of measles virus fusion protein. *Science*, 2024, 384 (6703), 10.1126/science.adm8693 . hal-04743230

HAL Id: hal-04743230

<https://hal.science/hal-04743230v1>

Submitted on 18 Oct 2024

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Copyright

A neutralizing antibody prevents post-fusion transition of measles virus fusion protein

2

Authors:

4 Dawid S. Zyla¹, Roberta Della Marca^{2,3,4}, Gele Niemeyer^{1,5}, Gillian Zipursky^{2,3}, Kyle Stearns^{2,3}, Cameron
Leedale⁶, Elizabeth B. Sobolik⁷, Heather M. Callaway^{1#}, Chitra Hariharan¹, Weiwei Peng^{8,9},
6 Diptiben Parekh¹, Tara C. Marcink^{2,3}, Ruben Diaz Avalos¹, Branka Horvat¹⁰, Cyrille Mathieu¹¹, Joost
Snijder^{8,9}, Alexander L. Greninger⁷, Kathryn M. Hastie¹, Stefan Niewiesk⁶, Anne Moscona^{2,3,12,13},
8 Matteo Porotto^{2,3,4*}, Erica Ollmann Saphire^{1,14*}

Affiliations:

10 ¹Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA 92037, USA

²Center for Host-Pathogen Interaction, Columbia University Vagelos College of Physicians and Surgeons,
12 New York, New York, U.S.A.

³Department of Pediatrics, Columbia University Vagelos College of Physicians and Surgeons, New York,
14 New York, U.S.A.

⁴Department of Experimental Medicine, University of Campania 'Luigi Vanvitelli', 81100 Caserta, Italy

16 ⁵University of Luebeck, Ratzeburger Allee 160, 23562 Lübeck, Germany

⁶Department of Veterinary Biosciences, College of Veterinary Medicine, The Ohio State University,
18 Columbus, Ohio, USA.

⁷Department of Laboratory Medicine and Pathology Virology Division, University of Washington, Seattle,
20 WA, USA.

⁸Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht
22 Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH, Utrecht, The Netherlands

⁹Netherlands Proteomics Center, Padualaan 8, 3584 CH, Utrecht, The Netherlands

24 ¹⁰Immunobiology of Viral Infections, International Center for Infectiology Research-CIRI, INSERM U1111,
CNRS UMR5308, University Lyon 1, ENS de Lyon, Lyon, France.

26 ¹¹Centre International de Recherche en Infectiologie équipe Neuro-Invasion, TROPism and VIRal
Encephalitis (NITROVIRE), INSERM U1111 - Université Claude Bernard Lyon 1, CNRS, UMR5308,
28 Ecole Normale Supérieure de Lyon, Université Lyon, Lyon, France

¹²Department of Microbiology & Immunology, Columbia University Vagelos College of Physicians and
30 Surgeons, New York, New York 10032, United States

¹³Department of Physiology & Cellular Biophysics, Columbia University Vagelos College of Physicians and
32 Surgeons, New York, New York 10032, United States

¹⁴Dept. of Medicine, University of California San Diego. La Jolla, California 92037 United States

34 # current address: Department of Chemistry & Biochemistry, Montana State University

*Correspondence should be addressed to: mp3509@columbia.edu and erica@lji.org

36

Abstract (117 words):

38 Measles virus (MeV) presents a public health threat that is escalating as vaccine coverage in the general
40 population declines and as populations of immunocompromised individuals, who cannot be vaccinated,
increase. There are no approved therapeutics for MeV. Neutralizing antibodies targeting viral fusion are one
potential therapeutic approach but have not yet been structurally characterized or advanced to clinical use.
42 We present cryo-EM structures of pre-fusion F alone (2.1-Å resolution), F complexed with a fusion-
inhibitory peptide (2.3 Å), F complexed with the neutralizing and protective antibody mAb 77 (2.6 Å), and
44 an additional structure of post-fusion F (2.7 Å). *In vitro* assays and examination of additional EM classes
show mAb 77 binds pre-fusion F, arrests F in an intermediate state and prevents transition to the post-fusion
46 conformation. These structures shed light on antibody-mediated neutralization that involves arrest of fusion
proteins in an intermediate state.

48

Introduction

50 Measles virus (MeV) is an enveloped, single-stranded negative-sense RNA virus that is highly
52 transmissible (basic reproduction number (R_0) of 12-18) by the respiratory route. MeV belongs to the
54 *Paramyxoviridae* family and causes considerable morbidity and mortality despite the availability of safe and
56 effective MeV vaccines (1, 2). Measles accounts for more childhood deaths than any other vaccine-
58 preventable disease. MeV was presumed to be eliminated in the U.S. (*i.e.*, ≥ 12 months without transmission)
60 in 2000 (1). However, the reintroduction of the virus in recent years has resulted in a resurgence and repeated
62 outbreaks (2–6). There were 9 million cases worldwide in 2021 (7), over 10.5 million in 2022, and between
64 2022 and 2023, the WHO European region observed more than a 30-fold increase in cases, with 40 of 53
member states affected (8). American vaccine coverage is now below the $>95\%$ required for herd immunity
(see CDC reports (9–18)). Although outbreaks are usually attributed to the unvaccinated, cases also occur
in people who were previously vaccinated (6, 19, 20). Up to 5% of vaccine recipients do not develop
adequate protective antibodies, even after the recommended two-dose vaccination regimen, and even in
those who do develop protective antibodies, vaccine-elicited immunity likely wanes over time (21–26).
Even mild cases of measles infection can result in immune "amnesia" and loss of preexisting antibodies
against other infections, leaving measles-convalescent individuals more vulnerable to future diseases (27,
28). Rare, but severe complications of measles can lead to lethal MeV encephalitis (29, 30).

66 MeV infects via coordinated action of the hemagglutinin (H) and fusion (F) envelope glycoproteins
68 to mediate virus attachment to two cellular receptors, SLAMI/CD150 and Nectin-4, and entry into target
70 cells (31). Vaccination results in neutralizing antibodies against these two proteins. Earlier work suggested
72 that most neutralizing antibodies are directed against H and that anti-F antibodies elicited by the current
vaccine are poorly neutralizing (32–34). A better understanding of the structures of F protein, the
conformational changes of F that drive fusion, and whether antibody-mediated inhibition of conformational
change can result in *in vitro* neutralization and *in vivo* protection against MeV are needed.

74 F is initially synthesized as a precursor molecule (F_0), which is subsequently cleaved into two subunits: the
76 N-terminal F_2 and the C-terminal F_1 . These subunits remain linked via a disulfide bond (35). Three F_1 and
78 F_2 subunits assemble to form a pre-fusion F complex on the viral surface. This trimeric complex is kinetically
trapped in the metastable state. Under physiological conditions, fusion activation requires the engagement
of the H glycoprotein by the cell-surface receptor (36–40). Once this activation occurs, the pre-fusion F
protein undergoes a substantial conformational change, elongating and embedding the hydrophobic fusion
peptide into the membrane of the target cell. During the fusion process, F refolds into a stable 6-helix bundle
post-fusion structure formed by the tight association of the N-terminal heptad repeat (HRN) and the C-
terminal heptad repeat (HRC). This entire process brings the viral and cellular membranes in close proximity
and leads to membrane merger (41–48). However, before adopting the low-energy post-fusion state, the F
protein adopts a range of intermediate conformations, which require rearrangement of its domains.

86 Targeting the intermediate state of F is a potential antiviral approach. Although neutralizing
88 monoclonal antibodies offer lifesaving treatments for several viruses, none are currently available to prevent
or treat measles. Furthermore, no structural information is yet available for any antibody against MeV that
could be used to define epitopes or activities that prevent or treat infection. The monoclonal antibody (mAb)
for which structure and activities are documented here is one of the very few neutralizing mAbs described
90 against the MeV envelope fusion (F) protein (49, 50).

92

Results

94 ***Human chimeric mAb 77 potently inhibits MeV infection.***

96 We previously isolated and sequenced an F-targeted neutralizing mouse antibody mAb 77.4 (49,
98 50), and demonstrated that it inhibits MeV infection by blocking fusion (49). To facilitate future use as a
human therapeutic, we grafted the 77.4 variable regions into a human IgG1 framework to obtain a chimeric
antibody, now termed mAb 77, and assessed its *in vitro* and *in vivo* efficacy.

100 We first evaluated the antiviral activity of mAb 77 using an *in vitro* viral infection assay in which
102 Vero-human CD150 (Vero-huCD150/SLAM) cells were treated with serial dilutions of mAb 77. Two
distinct MeV F viral entry inhibitors were included as additional controls. One inhibitor, *N*-(3-cyanophenyl)-
104 2-phenylacetamide (compound 3G in (51)), binds to prefusion F and blocks H-mediated fusion activation
(52). The other inhibitor is an HRC-derived peptide termed HRC4, which binds to HRN in the pre-hairpin
intermediate and blocks the conformational transition to the 6-helix bundle (53). After treatment, cells were
106 infected with the MeV wt B3-eGFP virus. The mAb 77 potently inhibited infection with an IC₅₀ of 0.034
nM (5.1 ng/mL) (**Fig. 1A**), which was substantially better than both HRC4 and 3G, which blocked fusion
with IC₅₀ values of 1.17 nM and 150.12 nM, respectively.

108 To test mAb 77 for *in vivo* efficacy against MeV exposure, we used the cotton rat model of measles
virus infection (54, 55). Cotton rats were treated with 0.1 mg/kg (n=5) or 1 mg/kg (n=10) of mAb 77
110 intraperitoneally 12 hours before challenge with 10⁵ TCID₅₀ (*i.e.*, 50% tissue culture infectious) dose of
MeV wt B3-GFP. Antibody pre-treatment resulted in a significant reduction in viral replication as compared
112 to mock-treated animals that had an average titer of 3.6 log₁₀±0.8 TCID₅₀/g lung tissue (**Fig. 1B**). Three of
the animals pretreated with 0.1mg/kg mAb were virus negative, and two had reduced virus titers in lung
114 tissue (2.4 and 2.6 log₁₀ TCID₅₀/g lung tissue). Eight of the animals treated with 1 mg/kg mAb were virus-
negative, and two had reduced virus titers (mean of 2.9 and 3.6 log₁₀ TCID₅₀/g lung tissue).

116

mAb 77 prevents conformational changes required for fusion.

118 The F protein is primed to undergo substantial conformational change and refolding to drive the fusion of
the viral and host membranes. These structural changes are triggered by a signal from the stalk region of the
120 H protein, which is activated once the globular head of the H protein binds to its cellular receptor (56). As a
first step in F conformational rearrangement, the N-terminal heptad repeat (contained in Domain III of the
122 F1 head region) refolds from three short helices and beta-hairpin motifs into a single, approximately 100 Å-
long helix. This assembled and now extended helix projects the fusion peptide, toward and into the host
124 membrane. This extended F conformation is often called the 'pre-hairpin intermediate' (57, 58). The
subsequent sequence of events remains elusive but, by analogy with other viruses, likely involves substantial
126 rearrangement and repositioning of the stalk region containing the HRC. This movement enables the HRC
to collapse onto the HRN into a 6-helix bundle that draws the viral and host membranes together to promote
128 fusion.

Previous studies demonstrated that murine mAb 77.4 inhibits the fusion of viral and host cell membranes,
130 but the step at which it functions remains unclear (49). The mAb 77 antibody could: (1) stabilize the F
prefusion conformation to prevent F from triggering; (2) allow triggering but stabilize the intermediate state
132 to prevent subsequent refolding and membrane fusion; or (3) impair F refolding by another mechanism.

To elucidate the stage of the fusion process at which mAb 77 acts, we used an assay that measures fusion
134 between transfected HEK293T cells with red blood cells (RBC) by quantifying the amount of hemoglobin
released upon lysis (**Fig. 2A and B**) (53). An integral component of this assay is the ability to release receptor
136 engagement by H so that anchoring of RBCs by H can be distinguished from anchoring by F. As RBCs do

138 not display either of the MeV receptors for wt H (*i.e.*, CD150/SLAM or nectin-4), we instead employed a
140 previously characterized chimeric protein that contains the MeV H stalk fused to the sialic acid receptor-
142 binding head domain of paramyxovirus human parainfluenza virus 3 (HPIV3) HN (53). The interaction of
144 the H-HN chimeric protein with the sialic acid displayed on the RBC surface can be reversed through
146 treatment with the small molecule zanamivir (59, 60). Hence, the H-HN chimera enables both reversible
148 attachment to RBCs and MeV H-driven triggering of F. H-HN and F transfected cells were first incubated
150 with RBCs at 4 °C to permit sialic acid binding but not fusion. The cell mixture was then treated with either
152 media or different viral entry inhibitors, and fusion was allowed to proceed for 60 mins at 37 °C. Treatment
154 with diluent media alone resulted in fusion of approximately 50% of total RBCs with the HEK293T cells
(**Fig. 2A and B, Fig. S1A, B**). The remaining RBCs had either begun, but not completed, fusion (irreversibly
bound through F) or had not yet initiated fusion (reversibly bound through HN only). Treatment with the
3G inhibitor prevented nearly all F-mediated anchoring, indicating, as previously reported, that this inhibitor
prevents F activation(53, 61). Meanwhile, treatment with the HRC4 peptide inhibitor resulted in most RBCs
being irreversibly bound, indicating that F was activated but could not complete fusion, as previously
described (53). Treatment with mAb 77 had the same effect as HRC4, where most RBCs were irreversibly
bound but not fused. We conclude from these results that, unlike 3G, mAb 77 does not completely prevent
the activation of F, nor does it inhibit the insertion of the fusion peptide into target cells. It does, however,
prevent the collapse of the pre-hairpin intermediate into the 6-helix bundle required for fusion, suggesting
that mAb 77 remains associated with an intermediate form of F.

156

Natural substitutions allow for production of MeV F in the pre-fusion state.

158 To structurally elucidate the mechanism of action of mAb 77, we first established a protein purification
160 protocol using a stabilized MeV F construct. Expression of the wild-type MeV F ectodomain (amino acids
1-495) results in the production of F in its post-fusion conformation only. Previous structural
162 characterization of MeV F was achieved by engineering four cysteines in the stalk region, which results in
disulfide linkages between the three protomers (52). However, the protein produced from this construct
164 aggregated, even at lower concentrations. As such, we instead generated a MeV F ectodomain that
incorporates two naturally occurring point mutations, E170G and E455G (**Fig. 3A**). These mutations were
166 derived from human central-nervous system isolates of MeV and stabilized F in the pre-fusion state (62,
63). When paired, stabilization was further enhanced (**Fig. S2A, B**). This F ectodomain, termed F_{ECTO}, was
168 ~95% cleaved by Furin, and approximately 85% of the resulting particles were in the pre-fusion
conformation (**Fig. S2 C, D**). Mass spectrometry revealed that all three predicted N-glycosylation sites were
occupied with oligomannose and (core-fucosylated) paucimannose glycans, as expected for the insect cell
170 expression system (**Fig. S7C**).

172 Although F_{ECTO} can be purified in the pre-fusion state, the protein refolds to the post-fusion state
over time. To determine how to maintain the pre-fusion conformation, we used differential scanning
174 fluorimetry (DSF) to systematically explore the impact of pH and salt concentration on the apparent melting
temperature (T_m^{app}) of F_{ECTO} (**Fig. S2 E, F**). Although pH had little influence on the T_m^{app} of F_{ECTO}, higher
176 salt concentration increased the T_m^{app} from 44.6 °C to 54.8 °C, at 60 mM and 1460 mM NaCl, respectively
(**Fig. S2 F**). Hence, buffering conditions of 800 mM NaCl and 50 mM HEPES pH 8.0 were used in the
subsequent purification of F_{ECTO}. We saw no F_{ECTO} in the post-fusion conformation even after more than 2
178 weeks of storage in this buffer (**Fig. S2 B**).

180 ***Structure of pre-fusion F***

182 We determined a 2.11-Å resolution cryo-EM structure of F in its unbound, pre-fusion state to investigate the
184 influence of the introduced stabilizing mutations (**Fig. 3B, Fig. S3 A, S4 A, S5 A**). This high-resolution
186 structure of the natural F_{ECTO} closely resembles the previous cysteine-stabilized prefusion F ectodomain with
two exceptions (52). First, loop 248-265 adopts a different conformation likely attributable to previous
crystal contacts (**Fig. S6A, B, C**). Second, the alpha helices of the HRC in the ectodomain stalk resolved
here begin to supercoil around each other starting at residue 473, whereas those in the Cys-stabilized
construct remain linear and do not supercoil (**Fig. S6A, B, C**).

188

Prefusion F in complex with inhibitor

190 We next solved the structure of F_{ECTO} in complex with [FIP-HRC]₂-PEG₁₁, a tandem peptide conjugate of
192 two copies each of FIP-HRC, linked by a PEG₁₁ moiety (53) (**Fig. 3C, Fig. S3 B, S4 B, S5 B**). As this
194 inhibitor contains both FIP, which stabilizes prefusion F, and an HRC mimic, which binds to the pre-hairpin
intermediate, it could theoretically capture either the pre- or post-triggered state of F, provided the correct
196 state is available for binding. We obtained a high-resolution structure of the F_{ECTO}-[FIP-HRC]₂-PEG₁₁
198 complex at 2.3-Å resolution (**Fig. 3C, Fig. S3 B, S4 B, S5 B**). Similar to the previous structure of MeV Cys-
stabilized F in complex with a related peptide inhibitor (52), here we find that FIP stabilizes F by occupying
the hydrophobic pocket created by F1 residues from all 3 protomers, an interaction that locks MeV F in the
200 prefusion state (52, 53, 64). All F_{ECTO} particles adopt a prefusion state with apparent density for FIP, but no
density for the HRC-derived peptide (**Fig. S6 D, E**). The lack of observable alternative conformations of F
and the lack of HRC density together suggest that a fusion-intermediate state was not available for HRC to
bind stably.

202

Prefusion F in complex with mAb 77

204 Our cell-based assays indicate that binding of mAb 77 locks F into an intermediate state of refolding, after
206 release of the fusion peptide, but before collapse of the trimer into the 6-helix bundle required to complete
fusion. The Fab of mAb 77 (Fab 77) binds F_{ECTO} with a K_D of 360 pM (0.36 nM) (**Fig. S2 E**), which is
208 consistent with its potent *in vitro* neutralization. To elucidate the binding epitope of mAb 77 and further
discern its mechanism of action, we obtained a F_{ECTO}-Fab 77 complex and determined its high-resolution by
cryo-EM (**Fig. S2 F**).

210 The final map of the F_{ECTO}-Fab 77 complex was resolved to 2.6-Å resolution, showing three copies of Fab
212 77 binding to the prefusion F_{ECTO} trimer (**Fig. 3E, Fig. S3 C, S4 C, S5 C**). The antibody epitope lies at the
base of the trimer and encompasses regions in both F1 and F2 from one protomer plus an additional F1 from
214 a neighboring protomer (**Fig. 3 D, E, G**). The heavy chain of Fab 77 contributes the bulk of the interaction,
burying 889 Å² of surface area on F_{ECTO}, whereas the light chain buries 106 Å² (**Table S2**). The predominant
216 interactions between the antibody and F_{ECTO} occur via the heavy chain complementarity-determining region
(CDR) 3, with additional contributions from CDR H1, CDR H2, and CDR L2 (**Fig 3G, Table S3**).

218 CDR H2 contacts F2_A residues W27, G37, and S40. CDR H1 residues Y27 and S31 form hydrogen bonds
with the backbone of residues L123 and V125, located in the fusion peptide of F1_B in the neighboring
220 protomer (**Fig. 3F**). Meanwhile, CDR-H3 occupies a shallow cleft between domains I and II of F1_B, forming
six hydrogen bonds and one salt bridge. F1_B residue R436 forms hydrogen bonds to the backbone oxygens
222 of CDR H3 residues Y105 and Y107 and a salt bridge with CDR H3 D109 (**Fig. 3H**). CDR L2 residues Y49
and Q55 also bind to this region, making a hydrogen bond with the backbone nitrogen of F1_B residue R435
and the hydroxyl group of S434 (**Fig. 3H, Table S4**). Together, this extensive network of 16 hydrogen bonds

224 and one salt-bridge anchor domains I and II of F1 in the prefusion state. Despite the glycan being closely
located to the Fab 77 epitope at N29, no interactions were observed between Fab 77 and N29.

226

F post-fusion structure

228 Our structure of F_{ECTO} in complex with Fab 77 unequivocally demonstrates that this mAb recognizes the
pre-fusion conformation of F and anchors the fusion peptide through interactions with CDR H1. However,
230 our RBC fusion assay (**Fig 2**) suggests that mAb 77 prevents viral infection by arresting the fusion process
after the fusion peptide has been released from the trimer and inserted into the host cell membrane.

232 To reconcile the structural finding that the Fab 77 epitope is in pre-fusion F, with the experimental data
suggesting that the Fab 77 stabilizes a transitional state after activation, we determined the cryo-EM
234 structure of MeV F in its post-fusion state. Direct structural comparison of the pre- and post-fusion states
from the same protein sequence would provide a more comprehensive understanding of the conformational
236 dynamics of F_{ECTO} and clarify how mAb 77 might selectively interact with the pre-fusion form or reveal
conservation of the epitope in the post-fusion form.

238 As mentioned above, storage of F_{ECTO} in a high-salt buffer promotes conformational stability, whereas
storage in a low-salt buffer induces spontaneous refolding to the post-fusion state. Hence, we incubated
240 F_{ECTO} in low-salt buffer (*i.e.*, 150 mM NaCl) and solved a 2.7-Å resolution cryo-EM structure of its post-
fusion conformation, using the same construct as represented in our pre-fusion F_{ECTO} structures (**Fig. 4 A,**
242 **B**).

Like post-fusion structures of other paramyxovirus F proteins, the MeV F_{ECTO} post-fusion structure adopts
244 a distinct elongated shape with a refolded head region and an extended 6-helix bundle composed of HRN
and HRC (41, 65–68), **Fig. 4A, B, Fig. S7A**). This conformational shift reduces the head radius by around
246 20% (from ~110 Å to ~93 Å) and extends the protein's long dimension by 60 Å (**Fig. S7 A, B**). The fusion
peptide (FP, residues 115-140) is part of the F_{ECTO} sequence, but we could not observe the corresponding
248 density for the fusion peptide, likely due to its inherent flexibility.

Alignment of the post-fusion structure of F_{ECTO} with its pre-fusion counterpart revealed that domain I
250 (residues 290-373) and the N-terminal part of F2 have the lowest degree of rearrangement during fusion and
provide a structural hinge about which the movement and rotation of other domains occur (45, 69) (**Fig.**
252 **4C**). In contrast, domains II (F1 residues 374-426) and III (F1 residues 115-287 and F2 residues 50-104)
show substantial spatial and structural rearrangement (**Fig. 4D, E, Fig. S7 B**). Although the majority of
254 domain II retains the immunoglobulin-like fold present in the pre-fusion conformation, residues 434-446 of
this domain, as well as the linker connecting domain II to HRC (residues 447-456), elongate as HRC
256 transitions from the "down" state to the "up" state as fusion proceeds. As a result, all of domain II shifts 4.3
Å toward domain I.

258 The most profound conformational change between the pre- to post-fusion state occurs in the fusion peptide
and HRN. Structural rearrangement within these regions includes refolding of HRN from several disjointed
260 helices and β-strands to one elongated helix, exposure of the buried fusion peptide, and a 52° rotation around
residue T287 (**Fig. 4D**). Overall, the conformational transition from pre- to post-fusion involves dramatic
262 refolding of the fusion peptide and HRN, as well as retention of the globular domain structure with
repositioning of the domains relative to their pre-fusion positions (**Movie 1**).

264 The major conformational shifts and repositioning of the three distinct components of the tripartite mAb 77
epitope clarify why this antibody cannot recognize F in its post-fusion state (**Fig. 4F**). Specifically, the
266 spatial rearrangement between domain II and the HRC, coupled with the movement of domain II relative to
domain I, lead to the dislocation of the mAb 77 epitope and loss of recognition of post-fusion F.

Preservation of the mAb 77 binding interface in MeV variants.

270 Although MeV has been generally considered to be serologically monotypic, genetic characterization of
 272 wild-type viruses identified eight clades (A-H) that can be further divided into 22 genotypes plus one
 274 additional proposed genotype (70–73). To evaluate whether natural genetic variation in MeV might impact
 276 mAb 77 binding, we examined sequence conservation across the available MeV F protein sequences in the
 278 NCBI database. Of the 550 residues in MeV F, 319 are fully conserved among the variants, but 231 (42%)
 280 have single or multiple amino acid substitutions (**Fig. 5A, B**). Within the mAb 77 epitope, however, only
 two residues, G37 and R436, vary across the range of known MeV sequences (**Fig. 5C**). The G37R mutation
 is extremely rare, occurring in only one instance (0.12% of sequences), but R436K occurs over 25% of F
 sequences. Binding of mAb 77 observed for wildtype F bearing an R436K mutation is similar, but mAb 77
 did not bind F carrying the rare G37R mutation (**Fig. S8 A, B, C**). In addition, the G37R mutation also
 decreased F-mediated fusion activity, which may be one reason for the low natural incidence of this
 substitution in circulating viruses (**Fig. 5D, Fig. S8D, E**).

282

mAb 77 interrupts the fusion cascade, leading to trimer disintegration.

284 Our structure of mAb 77 in complex with F, coupled with our post-fusion structure of F, clearly
 286 demonstrated that the epitope targeted by mAb 77 is specific to the prefusion conformation. However, our
 mechanistic fusion assay suggested that mAb 77 acts on F at an intermediate state, after F has been triggered
 and fusion activated, but before the 6-helix bundle has formed.

288 To further illuminate the mechanism by which mAb 77 inhibits viral entry, we investigated its
 impact on F_{ECTO} structure and stability. Specifically, we considered two (not mutually exclusive) hypotheses:
 290 (1) mAb 77 induces a conformational change in the epitope of F, potentially leading to the destabilization
 292 of the trimer, or (2) mAb 77 stabilizes both pre-fusion F_{ECTO} and an intermediate state, halting the refolding
 cascade from two arms. To test these hypotheses, we (a) compared the structure of F in the absence and
 294 presence of Fab 77 and (b) assessed the impact of Fab 77 on F thermal stability using differential scanning
 fluorimetry (DSF) and temperature-resolved dynamic light scattering (DLS). These complementary
 296 approaches enabled us to assess the overall stability of F and F-Fab 77 complexes (DSF) and monitor
 temperature-induced changes in protein conformation (DLS).

298 Alignment of the structures of F_{ECTO} alone and in complex with Fab 77 demonstrated high structural
 conservation, with a root-mean-square deviation (RMSD) of 0.75 Å over all C α or 1.24 Å over all atoms
 (**Fig. S9 A**). Residues involved in the mAb 77 epitope showed only minor differences between structures,
 300 with fusion peptide residues L123 and V125 having an RMSD of ~2 Å over all atoms (**Fig. S9 A, B**). Hence,
 binding of Fab 77 only marginally altered the conformation of F_{ECTO} .

302 DSF analysis demonstrated a modest increase in the thermostability of F when bound to Fab 77
 ($T_{\text{m}}^{\text{app}}$ of 47.6 °C vs. 51.6 °C in the unbound and bound state, respectively; **Fig. S9C**). This stabilization was
 304 more limited than that seen for [FIP-HRC]₂-PEG₁₁ (56.2 °C), but nevertheless suggests that binding of mAb
 77 does not inherently destabilize F_{ECTO} . Meanwhile, although DLS analysis also demonstrated that the
 306 temperature at which the F_{ECTO} -Fab 77 complex begins to unfold (i.e., $T_{\text{m}}^{\text{onset}}$) is similar to that of F alone,
 we found that the conformational behavior of the complex is markedly different (**Fig. S9D**). In the absence
 308 of Fab 77, the hydrodynamic radius (Rh) of F_{ECTO} is ~5.5 nm up to 44.7 °C, beyond which there is a steady
 temperature-dependent increase in Rh, likely reflective of the transition to the post-fusion state, followed by
 310 aggregation. Conversely, a clear plateau phase is observed for the F-Fab 77 complex, which remains arrested
 at an Rh of ~30 nm between 50 °C and 65 °C. This plateau is only surpassed above 65 °C, when Fab 77
 312 presumably unfolds and releases F. These data suggest that mAb 77 only modestly enhances the stability of

314 pre-fusion F but readily inhibits its collapse to the post-fusion conformation through stable association with
316 a fusion intermediate.

316 To visualize this potential intermediate(s) directly, we revisited our F_{ECTO}-Fab 77 cryo-EM dataset,
318 this time incorporating previously rejected Fab-bound classes. Through extensive 2D classification, we
320 identified several additional 2D class projections showing distinct Fab-induced F_{ECTO} conformations (**Fig.**
322 **6A**). Included in these projections was a complex of three Fabs bound to an F_{ECTO} trimer that is
324 conformationally distinct from that of the pre-fusion trimer. In this case, a part of the head region appears to
326 be drawn into the center of the F trimer, suggesting that a three-helix bundle would form upon release of the
fusion peptide and refolding of the HRN. We additionally observed a class in which one F_{ECTO} protomer was
dissociated from the trimer, leaving a "V"-shaped structure formed by the remaining two protomers, each
bound by a Fab 77 molecule. Last, we identified a 2D class in which Fab 77 is bound to a small F_{ECTO}
fragment (**Fig. 6A, B**). Similar 2D classes could be identified using time-resolved NS EM analysis, in which
F_{ECTO}-Fab 77 complexes were incubated for 1-10 mins at 50° C before grid preparation (**Fig. S10, Fig.**
S11A).

328 The scarcity of particles and views in the cryo-EM dataset hindered efforts to obtain 3D
330 reconstructions for the trimeric refolding intermediate and separated protomer complexes. However, we
332 successfully determined the structure of the Fab 77-stabilized F_{ECTO} fragment to 3.6-Å resolution (**Fig. 6C,**
Fig. S11B-F). This structure reveals that Fab 77 is bound to F_{ECTO} domains I and II as well as the N-terminal
segment of F2, in a manner similar to that of Fab 77 bound to pre-fusion F_{ECTO} (**Fig. S11G**). The lack of
density for the fusion peptide suggests that this region has been released from the Fab 77 epitope, a
possibility that is consistent with the results of our biochemical and cell-based assays.

334 Discussion

336 Most mAbs described thus far against measles virus are directed against the receptor-binding protein
338 H (74). The limited set of mAbs identified for the fusion protein F fall into two principal antigenic categories,
340 I and II (50). Category I mAbs are potently neutralizing, but susceptible to escape by naturally occurring
342 MeV variants. Category II mAbs typically exhibit less potent neutralization and protection in mice, yet offer
greater resilience against escape mutants. Where these antibodies specifically bind on the fusion protein is
currently unknown, as the precise epitopes have not been characterized. mAb 77 (mAb 77) is category II
but has high neutralization potency *in vitro* and protection *in vivo* (49, 50).

344 Several antibodies that bind the pre-fusion state of other paramyxovirus fusion proteins have been
346 described (68, 75–79), and for the paramyxovirus respiratory syncytial virus (RSV), two such antibodies are
348 in clinical use (80–82). In contrast to MeV, other paramyxovirus fusion proteins have three, rather than two,
major epitope classes: the apex of the head domain, the trimer interface where two protomers meet, and the
350 base of the head domain (**Fig S12 A-D**). Two mAbs that target Nipah virus F, 2B12 and 1H1, bind the base
352 of the head domain that encompasses primarily domain II with single interactions with either domain I
(2B12) or the cathepsin L cleavage site (1H1)(68). Here we show that mAb 77 against MeV also binds the
354 base of the head domain, but its quaternary epitope spans across 3 domains and 3 polypeptide chains (**Fig**
3F, H, Table S4). We hypothesized that mAb 77, like the Nipah mAbs 2B12 and 1H1, inhibits viral entry
356 by binding to pre-fusion F before it has been activated by H-receptor engagement on the target cell. This
mechanism differs from that of HRC peptide mimics, which interact with the F protein only after activation
of fusion when the virus has attached to the cell membrane, but before fusion has been completed (83, 84).
Unexpectedly, however, our mechanistic assays demonstrated that mAb 77 does not block any initiation of
conformational change. Instead, like HRC mimics, mAb 77 allows initial triggering but arrests the protein
at an intermediate step along the fusion pathway (**Fig. 2**).

358 Curiously, the quaternary epitope of mAb 77 includes, at its edge, the fusion peptide of F, which
360 extends from a neighboring protomer (*e.g.*, F_B) onto the top of domain II of F_A. However, the results of our
362 mechanistic assay indicate that the fusion peptide is released and inserted into the host membrane, despite
364 mAb 77 binding. We note that the fusion peptide makes a relatively small contribution to the overall epitope.
366 Indeed, only two of the 16 hydrogen bonds between mAb 77 and F involve the fusion peptide (CDR H1
368 Y27 and S31 with L123 and V125, respectively). Based on PISA server predictions, these interactions
370 contribute just -1.5 kcal/mol of free energy upon complex formation, in contrast to the -8.6 kcal/mol
372 discharged across the entire epitope. Hence, the fusion peptide, located on the edge of the epitope, could
potentially be extracted even though mAb 77 remains anchored to the N-terminal portion of F2 and the loop
between domain II and HRC. The stronger remaining interactions would likely still preclude HRC
repositioning, which requires release of the domain II-HRC loop. Furthermore, our structures suggest that
the fusion peptide is not necessarily the first region to refold upon fusion triggering. Instead, the refolding
of HRN from several disjointed sub-sections into an elongated helix could be the driving force for the
refolding that, once initiated, pulls the FP from its location atop the neighboring domain II, like a ribbon
from a box. This possibility is consistent with previous studies on refolding of the parainfluenza virus 5 F
protein examined by oxidative foot-printing and mass spectrometry (69).

374 Based on these biochemical and structural findings, we propose a model of mAb 77-mediated
376 protection against MeV that harmonizes our cell-based mechanistic studies with our biophysical and
378 structural observations (**Fig. 6D**). In this model, (1) mAb 77 anchors F in a prefusion state through extensive
380 interactions with two adjacent protomers. (2) Receptor engagement by H triggers refolding of F-HRN, and
release of the fusion peptide from the mAb 77 epitope. (3) Continued binding of F by mAb 77 prevents
complete refolding by anchoring F2 to domains I, II, and the linker in between. As a result, the binding of
mAb 77 arrests an intermediate between pre and post-fusion states.

382 It is not yet clear whether mAb 77-mediated stabilization of prefusion F would completely inhibit
384 F triggering in a natural viral infection or if the primary mechanism of action for this mAb is to prevent the
386 completion of fusion. Our temperature-dependent DSF and DLS experiments demonstrated that mAb 77
388 enhances the stability of prefusion F up to ~50 °C, after which the complex adopts a conformational species
390 distinct from that of apo-F. Meanwhile, our RBC-fusion assays indicated that F is activated at 37 °C, even
in the presence of mAb 77. These seemingly contradictory results may be explained by the stabilizing
mutations present in recombinant F_{ECTO} used for DSF and DLS experiments versus the destabilized, full-
length F used in the cell-based assay. It is also unclear whether the intermediate states captured by NS- and
cryo-EM reflect the structural trajectory of apo-F or if they are distinct states induced or enforced by mAb
binding. Nevertheless, our analyses demonstrate that in addition to stabilization of pre-fusion F, mAb 77
also prevents fusion by remaining bound to a post-triggered F.

392 This dual mechanism of antibody-mediated defense may also apply to other antibodies that are
394 specific for pre-fusion states. Several previous studies focusing on similar antibodies against Nipah, Hendra,
396 or parainfluenza viruses have primarily examined binding kinetics, neutralization efficiency, and structure,
398 but did not extensively explore mechanisms of activity. As a contrasting case, we have shown that the
400 HPIV3-neutralizing antibody PIA174 stabilizes the pre-fusion state of the protein (78). The only other
402 antibodies shown to recognize a refolding intermediate state of a viral fusion protein are the HIV-1 gp41-
404 specific monoclonal antibodies, 2F5 and 4E10. These rare antibodies were known to neutralize by targeting
a transient conformation during gp41-mediated membrane fusion. However, structures illuminating their
specific binding to the intermediate state are as yet unresolved (85). The structures presented here, of the
beginning and ending states of MeV F at high resolution, with additional lower-resolution views of captured
intermediates along the path, illuminate a mechanism of neutralization by conformational arrest of the fusion
protein at an intermediate, post-triggered state. This work paves the way for the next generation of measles
virus therapeutics and illuminates a mechanism that may be shared by antibodies against other viral
pathogens.

406 **Materials and Methods**

Plasmids

408 The genes of Measles morbillivirus (MeV) strains IC323 or B3 hemagglutinin protein (H), fusion protein
410 (F), human nectin 4, and human CD150 (huCD150/SLAM) proteins were codon optimized, synthesized,
412 and sub-cloned into the mammalian expression vector pCAGGS (Epoch Life Science). A codon-optimized
414 F protein sequence derived from the Measles virus strain Ichinose-B95a (Taxonomy ID: 645098) was
416 synthesized by GenScript and subcloned into the pcDNA3.1 vector. Stabilizing point mutations (E170G and
418 E455G) previously characterized in SSPE and MIBE measles strains were sequentially introduced using the
Q5 Site-Directed Mutagenesis kit (NEB). The ectodomain construct was generated by removing the
transmembrane region and cytoplasmic tail residues (496-550) using the Q5 Site-Directed Mutagenesis kit.
To generate *Drosophila* S2 stable cell lines, the F protein ectodomain construct E170G/E455G (F_{ECTO}) was
subcloned from the pcDNA vector to the pMT-puro vector, including a C-terminal enterokinase cleavage
site and a dual StrepII tag via NEB HiFi DNA assembly.

Cells

420 HEK293T (human kidney epithelial), Vero, and Vero- huCD150 (African green monkey kidney) cells were
422 grown in Dulbecco's modified Eagle's medium (DMEM; Life Technologies; Thermo Fisher Scientific)
424 supplemented with 10% fetal bovine serum (FBS, Life Technologies; Thermo Fisher Scientific) and
426 antibiotics at 37°C in 5% CO₂. The Vero-huCD150 culture medium was supplemented with 1mg/ml of
428 geneticin (Thermo Fisher Scientific). *Drosophila* S2 cells were cultured at 25°C without CO₂ in complete
Schneider's *Drosophila* Medium (Gibco) supplemented with 10% heat-inactivated fetal bovine serum (FBS)
and 1% penicillin-streptomycin (100 U/mL penicillin and 100 µg/mL streptomycin) or in serum-free Lonza
Insect Xpress Medium. ExpiCHO cells were maintained in ExpiCHO Expression Medium (Gibco)
supplemented with 8 mM L-glutamine in a humidified incubator at 37°C with 8% CO₂.

In vitro viral infection

430 Vero- huCD150 cells were plated in 96-well plates (1×10^4 cells/well). The following day, cells were treated
432 with serial dilutions of monoclonal antibody 77 (mAb 77); N-(3-cyanophenyl)-2-phenylacetamide, referred
434 to as 3G; or MeV F-derived HRC4 dimeric fusion inhibitory lipopeptide (*i.e.*, [HRC-PEG₄]₂-chol).
436 Simultaneously, cells were infected with MeV wt B3-eGFP for 3 h at 37°C (150-200 pfu/well). After 3 h,
438 the medium was replaced with medium containing 2% of methylcellulose Avicel/2× complete medium (1:1).
440 After 24 h, eGFP-infected cells were counted using a Cytation 5 (BioTek) and analyzed with Gen5 3.11
442 software (min object size 25 µm, max object size 135 µm, threshold 3,000). The samples were tested in
three experiments performed with technical duplicates in five-fold dilutions of 96-well plates. The
measurements from each plate were normalized using 100 nM of mAb 77, 25 µM of 3G compound, or 500
nM concentration of HRC4 as 100% inhibition. Data was analyzed in OriginPro 2023, where all biological
and technical replicates were globally fitted with logistic regression function with shared IC₅₀ and Hill slope
values, and A1 and A0 (highest and lowest signals) were used to normalize the data. Based on the normalized
data, percent inhibition was calculated using the following equation: $[1 - X] \times 100$, where X is the fraction of
the normalized signal.

444 ***Beta-Galactosidase (Beta-Gal) complementation-based fusion assay***

446 The Beta-Gal complementation-based fusion assay was performed as previously described (53, 60). Briefly,
448 HEK293T cells transiently transfected with nectin 4 or huCD150 and the β -Gal omega subunit are mixed
450 with cells co-expressing glycoproteins F and H and the β -Ga alpha subunit. Cell fusion leads to alpha-omega
452 complementation and is measured in the presence or absence of fusion inhibitory compounds. Fusion is
stopped by lysing the cells and, after addition of the substrate (®The Tropix Galacto-Star™
chemiluminescent reporter assay system, Applied Biosystems), fusion is quantified on either a Tecan
M1000 microplate reader or a Biotek Cytation 5. Three biological replicates were recorded, and globally
fitted with a logistic function in OriginPro 2023. Obtained parameters were used to normalize the data per
sample and plotted with standard error calculated from all data points.

454 ***Cell surface staining with conformation-specific anti-F mAbs***

456 HEK293T cells were transiently transfected with viral glycoprotein constructs. The transfected cells were
458 incubated at the temperatures and times indicated in the figures. Specific MeV F conformations were
detected with mouse mAbs followed by Alexa-488 anti-mouse secondary antibody (Life Technologies) and
DAPI (4',6-diamidino-2-phenylindole; Thermo Fisher) staining. Plates were imaged with a Cytation5, and
the relative fluorescence of antibody-bound cells was determined using BioTek Gen5.

460 ***Viral rescue***

462 HEK293T cells were transfected using Lipofectamine 2000 in 6-well plates coated with poly-D-lysine. The
transfection mixture included cDNA constructs coding for viral proteins N (GS6558900-1), P (GS59482),
464 and L (GS58944), all sourced from Epoch Life Science according to our design specifications. Additionally,
cDNA for T7 polymerase (GS58929) and the genome for the MeV B3 eGFP wt virus (GS68838) were
466 included. Cells were incubated overnight at 37°C in Opti-MEM medium. The medium was then replaced
with DMEM supplemented with 10% FBS. Cells were then subjected to a heat shock treatment by incubating
468 them at 42°C in a water bath for 3 h. Subsequently, the cells were returned to 37°C for 48 hrs. The cells
were then detached and co-incubated with Vero-huCD150 cells in T75 flasks to facilitate rescued virus
470 amplification. The virus underwent four passages and was titrated to a concentration of 10^6 plaque-forming
units per milliliter (PFU/ml). The virus sample was then sequenced and used in subsequent *in vitro* and *in*
vivo experiments.

472 ***In vivo experiments: Cotton rats***

474 Inbred cotton rats (*Sigmodon hispidus*, cotton rat strain “Hsd:Cotton Rat” without genetic modifications)
were purchased from Envigo, Inc., Indianapolis. Male and female cotton rats aged 5 to 7 weeks were used
476 for experiments. For intranasal infection, 10^5 TCID₅₀ of MeV (strain B3 wt eGFP) was inoculated
intranasally to isoflurane-anesthetized rats in a volume of 100 μ l. Animals received intraperitoneally either
478 the indicated amount of mAb 77 or vehicle 12 hrs prior to infection. Four days after infection, animals were
euthanized by CO₂ inhalation, and their lungs were collected and weighed. Lung tissue was homogenized
with a glass dounce homogenizer. Supernatants were serially diluted and titrated for infectious virus on
480 Vero-huCD150 cells in 48-well plates. Plates were scored microscopically for cytopathic effect (CPE) after
7 days, and the tissue culture infectious dose 50 (TCID₅₀) was calculated. The results are presented as
482 TCID₅₀/g of lung tissue.

Red Blood Cell (RBC) fusion assay

484 To investigate the specific stage at which mAb 77 affects the fusion process, we used a previously
486 characterized assay involving RBCs and HEK293T cells transfected with a chimeric version of MeV H and
488 MeV F bearing a T461I mutation (53, 60). The chimeric version of H (termed H-HN) contains the stalk
490 region of MeV H to maintain interaction with MeV F fused to the sialic acid receptor-binding domain of
492 human parainfluenza virus 3 (HPIV3) HN protein. The interaction between H-HN and sialic acid receptors
on RBCs can be reversed through treatment with zanamivir, which enables the differentiation of F-mediated
anchoring from H-mediated anchoring. The T461I mutation was introduced into the F protein to reduce its
stability and enhance fusion activation. Each of these specific proteins have been used in previous studies
(53, 60).

Transfected HEK 293T cells were incubated with a 1% v/v of RBCs in CO₂-independent media for
30 min at 4°C to allow for receptor binding without initiating the fusion process. Following this incubation
period, the cells were washed three times with serum-free medium to remove unbound RBCs. The cells
were then exposed to either diluent medium or mAb 77. MeV-F targeted inhibitors with known functions
were also included as controls. These included the compound 3G (*N*-(3-cyanophenyl)-2-phenylacetamide),
which prevents H-mediated fusion activation by binding to prefusion F (51), and a peptide derived from the
heptad repeat C (HRC) region, named HRC4 (83), which obstructs the conformational transition necessary
for fusion by interacting with the heptad repeat N (HRN) in the pre-hairpin intermediate state.

Following these treatments, the cell mixtures were warmed to 37°C for 60 min to activate F-
mediated fusion of the RBCs and 293T cells. The outcomes of these interactions were classified into three
groups: 1) reversibly bound RBCs; 2) irreversibly bound but not fused RBCs; and 3) RBCs that had
successfully fused with HEK293T cells. Each population was quantified through measurement of
hemoglobin as detailed below (see also **Fig. S1A** for an experimental schematic).

The assay is performed in poly-D-lysine biocotated 24-well plates on which HEK 293T cells are
plated and transfected with the viral glycoproteins. The plates are then treated overnight at 37°C with 25
mU/well of exogenous neuraminidase to prevent cell-to-cell fusion and maintain an intact cell monolayer.
The following day, the plates are transferred to melting ice (4°C) for 30 minutes, washed with cold CO₂-
independent media, and then incubated with RBCs (1%v/v) for 30 minutes. After this incubation, the
unbound RBCs are washed from the cell surface, the treatments are added, and the cells are incubated at
37°C. Afterward, the plates are transferred to melting ice (4°C) for assessment of the different populations
of RBCs (reversibly bound, irreversibly bound, and fused). Reversibly bound RBCs (group 1) were
separated from the cells expressing the viral glycoproteins by treating the wells with 10mM zanamivir for
30 mins at 4°C. The addition of zanamivir allows the resuspension of the RBCs in the supernatant fluids,
whereas the cells expressing the viral glycoproteins remain attached to the plastic in the well. The
supernatant fluids containing the reversibly bound RBC were moved in V-bottomed 96-well plates and spun
down. The RBCs remained at the bottom of the V-bottomed well and the supernatant was removed and
replaced with ACK-Lysing buffer (ammonium-chloride-potassium, from Gibco A10492-01) to released in
solution the hemoglobin. Irreversibly bound RBCs (group 2) were measured by incubating the cells (minus
the removed, reversibly bound RBCs) with ACK-Lysing buffer (ammonium-chloride-potassium, from
Gibco A10492-01) for 30 mins at 4°C. ACK buffer selectively lyses (unfused) RBCs by disrupting the
internal ionic balance, resulting in the release of hemoglobin directly into the media. The hemoglobin is
released in the supernatant fluids that are transferred to 96-well plate for hemoglobin quantification. The
remaining cells (still bound to the plastic in the well) are fusions of RBC and HEK 239Ts (group 3) and are

526 ACK buffer insensitive. To release the hemoglobin, this population of cells were lysed with 50 mM HEPES
528 (Gibco Cat#15630080), 100 mM NaCl, and 5 mg/mL dodecyl maltoside (Thermo Scientific Cat#89903)
(DH buffer) and clarified via centrifugation. Lysate was then moved to flat-bottomed 96-well plates for
hemoglobin quantification.

530 The level of hemoglobin was quantified for each group by measuring the absorbance of each lysate
at 410 nm. The amount of hemoglobin in each group was added together to represent 100%. Each group is
532 displayed as a fractional proportion of this normalized value.

F_{ECTO} purification

534 *Drosophila* S2 cells were transfected with a plasmid encoding the F ectodomain construct (pMT-puro-
F_{ECTO}2M-EK-twin-Strep-TagII) following the manufacturer's protocol (referred throughout the text as F_{ECTO}
536 for simplicity). On day 1, S2 cells were seeded in a 6-well plate (1.0×10^5 – 1.5×10^5 cells/mL) in 3 mL of
complete Schneider's medium. On day 2, the cells were transfected with 2 μ g of the plasmid using the
538 Effectene (QIAGEN) transfection protocol. Selection with puromycin (6 μ g/mL) started on day 5, at which
point cells were transferred to a T25 flask. The cells were then gradually expanded to a T75 flask, with the
540 medium replaced by Lonza Insect Xpress medium containing 6 μ g/mL puromycin. Subsequently, cells were
expanded to 2 x 1 L in 2 L shaking flasks, induced with 500 μ M CuSO₄ at 1×10^7 cells/mL, and harvested
542 four days post-induction. Cells were removed from the culture medium by centrifugation at 5,000 x g for 20
min. The medium was adjusted to pH 8.0 with 1 M HEPES, and Biolock (IBA) (2.4 mL/L of medium) and
544 NaCl (to a final concentration of 800 mM) were added. The medium was loaded onto a StrepTrap HP 5 mL
column (Cytiva), and the column was washed with high-salt HBS (50 mM HEPES pH 8.0, 800 mM NaCl)
546 until a stable UV absorbance at 280 nm was achieved. The protein was then eluted with high-salt HBS
containing 5 mM d-desthiobiotin (Sigma). Next, the eluted protein fractions were pooled, and the buffer was
548 exchanged for high-salt HBS using a HiPrep 26/10 Desalting column (Cytiva). Finally, the purified protein
was flash-frozen in liquid nitrogen. Protein concentration was estimated using the molar extinction
550 coefficient at 280 nm ($48,820 \text{ M}^{-1} \text{ cm}^{-1}$).

Antibody expression

552 Monoclonal antibody 77 (mAb 77) was produced in ExpiCHO cells by following the manufacturer's high-
titer transfection protocol using the pTRIOZ-mAb 77 plasmid, which encodes the antibody heavy and light
554 chains. After seven days of expression, cells were removed from the culture medium by centrifugation at
4,000 x g. The medium was then adjusted to pH 8.0 with 1 M HEPES (pH 8.0) and incubated overnight at
556 4°C with protein A agarose beads to capture the mAb 77. On a subsequent day, the beads were washed with
20 ml of HBS, and the bound antibody was eluted using 15 mL 0.2 M glycine (pH 2.0). The eluate was
558 immediately neutralized by adding 10% (v/v) 1 M HEPES (pH 8.0).

To generate antibody fragments (Fabs), mAb 77 was digested at 1 mg/ml with 1% (w/v) cysteine-
560 activated papain for 4 h at 37°C in a water bath. The enzymatic reaction was halted by adding 0.5 M
iodoacetamide to a final concentration of 50 mM. Following digestion, the reaction mixture was diluted 10-
562 fold with 10 mM HEPES (pH 8.0) to decrease salt concentration and loaded onto a 1 mL Mono S column
pre-equilibrated with 20 mM HEPES (pH 8.0). The Fabs' flowthrough was collected, and the Fc fragments
564 were eluted using a single step with 20 mM HEPES (pH 8.0) containing 2 M NaCl. The isolated Fabs were
concentrated, and their buffer was exchanged for HBS. The Fabs were stored at 4°C for further analysis and

566 experimentation. Protein concentration was estimated using the molar extinction coefficient at 280 nm (mAb
567 77: 240360 M⁻¹ cm⁻¹, Fab 77: 84,270 M⁻¹ cm⁻¹).

568 ***Formation of F_{ECTO}-Fab 77 Complex***

569 The F_{ECTO} and Fab 77 complex was prepared by incubating approximately 5 μM of F_{ECTO} with a three-fold
570 molar excess of Fab 77 at 4°C overnight in HBS (50 mM HEPES, pH 8.0, and 150 mM NaCl). Following
571 the incubation, the mixture was subjected to size-exclusion chromatography using a Superdex 200 Increase
572 10/300 GL column (Cytiva) in HBS. The fractions containing the F_{ECTO}-Fab 77 complex were collected,
concentrated, and used on the same day.

574 ***Differential Scanning Fluorimetry (DSF) Assay***

575 Differential Scanning Fluorimetry (DSF) was used to determine protein stability and evaluate variations in
576 thermal denaturation profiles under distinct buffer conditions (86). Each analysis was conducted using 25
577 μL containing 2.5 μg of protein and 2.5 μL of a 1% SYPRO Orange solution (Thermo Scientific), with the
578 remaining volume composed of the buffer being tested. Stability measurements for F_{ECTO}, F_{ECTO}-Fab 77,
579 F_{ECTO}-[FIP-HRC]₂-PEG₁₁ (described in (53)) were performed in HBS. For pH screening, buffers contained
580 50 mM Sodium Acetate (pH 5.0), Bis-Tris (pH 6.0), MOPS (pH 7.0), HEPES (pH 8.0), or CAPSO (pH 9.0).
581 The salt screening was performed using 50 mM HEPES (pH 8.0) with NaCl concentrations ranging from 0
582 to 2 M.

583 The samples were dispensed into a 96-well PCR plate (BIO-RAD Multiplat 96-Well PCR Plates,
584 low profile, unskirted), and the plate was then sealed (Bio-RAD Microseal 'B' PCR Plate Sealing Film) to
585 prevent evaporation during the heating process. A thermal cycling procedure was initiated on a Bio-Rad
586 CFX 96 thermocycler, with the temperature incrementally elevated from 25°C to 95°C at a rate of 1°C per
min.

587 Throughout thermal cycling, SYPRO Orange fluorescence was monitored continuously with the
588 wavelengths for excitation and emission set at 520 nm and 540 nm, respectively. Data analysis was
589 automatically carried out in Bio-RAD CFX Manager software, and the first derivative of the melting curve
590 was graphed against temperature. Each experimental condition was performed in quadruplicate, and the
591 average derivative signal was calculated. The averaged derivative signal minimum represented the protein's
592 apparent melting temperature (T_m^{app}).

594 ***Dynamic light scattering***

595 Dynamic Light Scattering (DLS) experiments were performed using a Dynapro PlateReader-2 (Wyatt)
596 instrument with Corning 384-well plates with clear bottom. Four independent replicates were recorded for
597 each sample, and 25 μL of protein at 0.05 mg/ml was added to each well. The temperature ramp was set to
598 increase at 0.2°C per min from 25 °C to 70 °C, resulting in a 1 °C ramp per cycle. The autocorrelation
599 function for each replicate was fitted using regularization fit in DYNAMICS 7.8.1.3 software (Wyatt), and
600 the radius of the dominant mass species was plotted against temperature. 10% of the total signal change was
601 used to calculate the temperature onset, which was manually estimated for the obtained curves. For the Fab
602 77 fitting, the maximum signal was fixed at double the last measured point. The resulting plots were
generated using Matplotlib.

604 ***Bio-layer interferometry***

BLI-based kinetic analysis was conducted using the OctetRed384 system (Sartorius). Anti-human Fab (FAB2G, Sartorius) capture sensors were loaded with Fab at 15 $\mu\text{g}/\text{mL}$ in 10 mM HEPES (pH 7.4), 150 mM NaCl, 3 mM EDTA, 0.05% Tween-20, 0.5 mg/ml BSA (1xHBSTE/BSA). Binding of F_{ECTO} to Fab-loaded sensors was performed using two-fold serial dilutions of F_{ECTO} . Baseline and dissociation steps were carried out in 1xHBSTE/BSA. Regeneration was carried out using 10 mM Glycine (pH 2.5). Reference sensors (those not loaded with Fab but dipped into F_{ECTO} -containing wells) were subtracted from each dataset to account for non-specific F_{ECTO} binding. Fab-only sensors were used as sample references. Kinetic parameters (K_{on} and K_{off}) and affinities (K_{D}) were calculated from a nonlinear fit based on the 1:1 binding kinetic model of the data using the Octet Data Analysis HT software version 11 (Sartorius). Three replicates for each binding curve were performed.

Structural mapping of protein variants

616 The sequences for MeV F proteins were acquired using a custom Python script using the BioPython library (87). This script was used to query the Entrez protein database for "Measles morbillivirus Fusion." All results obtained from this process were consolidated into a single FASTA file.

The sequences were then filtered based on size, retaining only those longer than 400 and shorter than 600 amino acids. Subsequently, the Needleman–Wunsch algorithm inside BioPython was employed for pairwise alignment with the F wt sequence (Uniprot: Q786F3) to curate the sequences further. Any sequences with low alignment scores (lower than 0) were removed from consideration.

624 After this curative process, the filtered FASTA file was globally aligned using the Clustal Omega software (88). This global alignment was stored in a clustal format file, which was then used to calculate the sequence conservation for each position using the AL2CO program (89). Primary sequence conservation was visualized and graphed using Matplotlib and Seaborn Python packages (90, 91).

628 Structural sequence conservation was mapped onto the pre- and post-fusion structures of F_{ECTO} using ChimeraX 1.6, which also uses AL2CO (92). Statistics regarding the point mutations at the mAb 77 epitope were computed in Python based on the Clustal alignment.

630 ***Cell Surface Biotinylation***

HEK 293T cells were seeded in a 6-well plate and transfected with measles B3 F proteins (wildtype-wt, 436K, 436G, 436D, 37R) or measles H, by mixing 2 $\mu\text{g}/\text{well}$ of plasmid in OPTIMEM with 4 $\mu\text{g}/\text{well}$ of Lipofectamine 2000 (Invitrogen Cat#11668019) in OPTIMEM (Gibco Cat#31985088) for 20 min at room temperature and incubating with cells for 3 hrs at 37 $^{\circ}\text{C}$. After transfection, cells were incubated with DMEM (Gibco Cat#10569044) with 10% FBS (Gibco Cat#16000044) and 1% Penicillin-Streptomycin (Gibco Cat#15140122) at 37 $^{\circ}\text{C}$ or 32 $^{\circ}\text{C}$ for 24 or 48 hrs. Cells were then incubated at 4 $^{\circ}\text{C}$ with 3.3 mM NHS-S-S-dPEG₄-biotin (Quanta Biodesign Cat#10194) in DPBS (Gibco Cat#14287080) for 1 hr before lysing with DH Buffer [50 mM HEPES (Gibco Cat#15630080), 100 mM NaCl, 5 mg/mL dodecyl maltoside (Thermo Scientific Cat#89903) in Milli-Q Water] supplemented with cComplete Protease Inhibitor Cocktail (1 tablet/50 mL; Roche Cat#11836145001). Biotinylated proteins were incubated with Streptavidin Sepharose beads (Invitrogen 434341) for 16 hrs at 4 $^{\circ}\text{C}$. Protein was eluted from washed beads in reducing Laemmli SDS Sample Buffer (Boston BioProducts Cat#BP-110R), boiled for 10 min, and run on a 4-20% Novex Tris-Glycine Protein Gel (Invitrogen Cat#WXP42026BOX). The gel was transferred to nitrocellulose using an iBlot quick transfer method (Invitrogen IB23001). The membrane was blocked (Invitrogen

646 Cat#WB7050), treated with Anti-Measles F HRC (GenScript; Rabbit) and alkaline phosphatase-conjugated
anti-rabbit secondary antibody (Invitrogen Cat#WB7105). The blot was then developed using NBT/BCIP
648 Substrate (Invitrogen Cat#WP20001). Analysis of the blot was performed with GelAnalyzer 23.1 and the
integrated intensity of the bands was normalized to the expression level of F wt at 37 °C.

Grid preparation

650 Negative stain

651 Copper grids (400 mesh) coated with carbon film (CF400-Cu, Electron Microscopy Sciences) were used for
652 negative staining. The grids were first subjected to glow discharge treatment using the easiGlow Glow
Discharge Cleaning System (Pelco) for 15 sec at 15 mA to enhance hydrophilicity. Next, the protein sample
654 concentration was adjusted to 0.01 absorbance units at 280 nm, and 3 μ L of the sample was applied to the
grid for a 1 min incubation. Subsequently, the grid was blotted to remove an excess sample and washed
656 three times with 3 μ L deionized water, blotting between each washing step. The grid was incubated with 3
 μ L 1% uranyl acetate solution for negative staining. After two blotting steps, a final drop of the staining
658 solution was added, followed by a 1 min incubation. The grid was then blotted once more to remove excess
stain and allowed to air-dry.

660

Graphene oxide grids

661 Graphene oxide (GO) grids were prepared in-house by diluting a commercial GO solution (2 mg/mL, Sigma-
Aldrich) in deionized water to a final concentration of 0.2 mg/mL. This diluted solution was sonicated for 5
664 min in a water bath to ensure proper dispersion of GO layers. Next, large aggregates were removed via
centrifugation at 500 x g for 1 min. Finally, the supernatant containing the dispersed GO was collected by
666 transferring the upper 50% solution to a fresh 1.5 mL microcentrifuge tube.

667 Quantifoil R2/2 grids were washed with ethyl acetate overnight and glow-discharged under the same
668 conditions as the negative stain grids. Then, 3 μ L of the GO solution was applied to the grids and incubated
for 4 min. The grids were blotted, rinsed with 20 μ L deionized water, blotted once more, and air-dried for at
670 least 10 min.

671 On the same day of grid preparation, dried GO grids were used for protein sample vitrification. The
672 Vitrobot Mark IV plunge-freezing system was operated at 4 °C and a relative humidity of 100%. A 3 μ L
aliquot of the protein sample (0.2 – 0.5 mg/mL) was deposited onto the GO grid, followed by a 12 sec
674 incubation period. After the incubation, the excess sample was blotted away (blot force 0) for 3 sec. The
grid was immediately plunge-frozen in liquid ethane cooled by liquid nitrogen.

676

C-flat grids

677 C-flat 1.2/1.3 400 mesh grids were glow discharged and immediately used for sample freezing. A 3 μ L
678 aliquot of 0.5 mg/mL protein sample was deposited onto the grid, immediately blotted for 6 sec, and plunge-
680 frozen in liquid ethane cooled by liquid nitrogen.

Cryo-EM data processing

682 FECTO-Fab 77

683 Movies were collected on a Titan Krios operated at 300 KV using a K3 Direct electron detector (Gatan) in
684 counting mode (0.66 Å pixel⁻¹) at a nominal magnification of \times 130,000 using a defocus range of -0.5μ m
to -2.0μ m with the BioQuantum energy filter slit set to 20 eV. Movies (LZW compressed TIFF files) were

686 collected in EPU (Thermo) over a 3 sec exposure with an exposure rate of $\sim 15 \text{ e}^- \text{ pixel}^{-1} \text{ sec}^{-1}$, resulting in
688 a total exposure of $\sim 50 \text{ e}^- \text{ \AA}^{-2}$ ($1 \text{ e}^- \text{ \AA}^{-2} \text{ frame}^{-1}$). Downstream processing was done using Relion, homemade
690 Relion scripts (https://github.com/dzyla/cryoem_notebook;
https://github.com/dzyla/Follow_Relion_gracefully), and cryoSPARC (93–96). Frame alignment was done
692 in Relion 4 using MotionCor2 version 1.4.0 with 6x5 patches and a B factor of 150 (97). CTF determination
694 was performed using CTFFIND4 version 4.1.14 using dose-weighted micrographs (98).

692 Particles were auto-picked in Relion from randomly selected micrographs using the Laplacian-of-
Gaussian algorithm, extracted at 512 px box size and Fourier-cropped to 64 px (5.28 Å/px), and used for the
694 2D classification step. Next, particles resembling glycoprotein were selected and subjected to further rounds
of 2D classification. The best classes showing different glycoprotein orientations were selected and used for
696 Topaz model training over 10 epochs with $\sim 10,000$ particles (99). Finally, the optimized model was used to
pick particles in the whole dataset. Approximately 1.1M particles were extracted in Relion, imported into
698 cryoSPARC, and subjected to 2 rounds of 2D classification. Classes resembling glycoprotein with bound
Fab were selected (148,000 particles), and particles corresponding to Fab only were discarded. Selected
700 particles from cryoSPARC were transferred back to Relion using a homemade script and re-extracted at 512
px with Fourier-cropping to 160 px (2.112 Å px⁻¹). Particles were again imported to cryoSPARC, where the
702 initial model was generated. The obtained model was used for the 3D classification in Relion with 3 classes.

During the first 25 iterations, global angular searches were performed using 15° sampling intervals.
704 Once the classification reached equilibrium (followed by monitoring class distribution using Follow Relion
Gracefully (96)), the 3D classification job was resumed with local angular searches of 7.5° sampling
706 intervals and a 30° local angular search range. This procedure was repeated with a decreasing angular
sampling interval and search range (kept double the angular sampling) until there was no improvement in
708 estimated angle accuracy. Two classes showed high-resolution features and were selected for the 3D Refine
protocol (142,000 particles). Next, refined particles were re-extracted at 512 px with Fourier-cropping to
710 320 px (1.056 Å px⁻¹) with recentering coordinates. Finally, particles were refined, post-processed, and CTF
and aberration refinement were performed. This procedure was repeated until there was no improvement in
712 the reported post-processing resolution. Then, the Polishing step was applied, first by training on 10,000
particles with the fraction of Fourier pixels for testing set to 0.5. The obtained trained parameters were used
714 for particle polishing, and particles were extracted at 320 px (1.056 Å px⁻¹). Particles were again 3D refined,
and CTF and aberration refinement were performed until there was no further improvement in the reported
716 post-processing resolution. Finally, polished particles were imported into cryoSPARC, and a non-uniform
refinement protocol was used to generate the final cryo-EM map in C3 symmetry. Then, particles were C3
718 symmetry expanded and refined using the Local Refine protocol in cryoSPARC to obtain the final map. The
final resolution reported in the manuscript was calculated in cryoSPARC at FSC=0.143 for all maps.

720
F_{ECTO} [FIP-HRC]₂-PEG₁₁
722 The F_{ECTO}-[FIP-HRC]₂-PEG₁₁ structure was recorded and processed following the same workflow as the
F_{ECTO}-Fab 77 structure. The number of particles and workflow overview is presented in **Fig. S5B**.

724
F_{ECTO}
726 The F_{ECTO} dataset was acquired as described above, with minor modifications. An increased electron
exposure of 70 e⁻/Å² was used for data acquisition. Initial data processing was conducted in cryoSPARC
728 version 4.3 Live, where 4.6M particles were extracted from 7,980 micrographs through blob picking. A deep

730 2D classification protocol in cryoSPARC was applied to these particles, from which the best candidates were
selected for training of the Topaz model. After Topaz extraction, 12M particles were extracted at a box size
of 420 px and Fourier-cropped to 64 px.

732 Through intensive deep 2D classification, a final dataset comprising 1.7M particles of high quality
was obtained. These particles were then subjected to an initial 3D reconstruction to recenter 3D coordinates,
734 after which they were re-extracted at a box size of 420 px and Fourier-cropped to 300 px. A 3D
reconstruction from Homogeneous refinement yielded a resolution of 2.19 Å in C3 symmetry. After
736 symmetry expansion to C3, the particles were classified into 10 distinct classes through 3D classification in
cryoSPARC, with a high-resolution limit set at 2.0 Å. The class with the highest resolution, 2.11 Å, was
738 selected for further processing. Local and global CTF refinements were performed, and the final refinement
was done using a local refinement protocol. Detailed processing is shown in Fig S5 A.

740

Post-fusion F_{ECTO}

742 F_{ECTO} was incubated in lower salt buffer (50 mM HEPES pH 8.0, 150 mM NaCl) for 1 week at 4°C.
Quantifoil R1.2/1.3 grids were used to freeze F_{ECTO} in post-fusion confirmation. F_{ECTO} (3 µL of 0.5 mg/ml)
744 was mixed with 1 µL 0.36 mM Lauryl Maltose Neopentyl Glycol (LMNG), blotted for 6 s, and frozen in
liquid ethane. The data processing was similar to the F_{ECTO}-Fab 77 dataset. For the post-fusion conformation,
746 data processing involved selecting particles based on size and shape, specifically top views of approximately
70 Å in diameter and extended side views. The detailed processing is illustrated in Figure S5 D.

748

Fab 77-stabilized F_{ECTO} fragment and refolding intermediates

750 To determine the structure of the F_{ECTO} fragment stabilized by Fab 77, we reprocessed the F_{ECTO}-Fab 77
dataset in cryoSPARC 4.4. Corrected movies were imported, and Patch CTF was used to estimate the
752 contrast transfer function values. A permissive blob picker (80-120 Å, 0.2 minimum separation distance)
yielded 5.6M particles, which underwent Deep2D classification. Classes corresponding to F_{ECTO}-Fab 77 and
754 unresolved junk classes were rejected, and the remaining particles were used for multiple rounds of Deep2D
classification. Finally, 17,000 particles showing intermediate states of refolding were used to train the Topaz
756 model. After extraction, particles were divided into those containing the Fab 77-stabilized F_{ECTO} fragment
and intermediate refolding steps. For refolding intermediates, ~35,000 particles were selected, and ~700
758 corresponded to the intermediate refolding step, ~2,000 to the protomer-separated state, and ~230,000 to the
Fab 77-stabilized F_{ECTO} fragment. The latter were re-extracted at 340 px, and Fourier cropped to 160 px.
760 Extracted particles were again subjected to Deep2D classification using a high-resolution information cutoff
at 3 Å. Only the best-looking classes were selected (94,000), and the initial model was calculated with high-
762 resolution information up to 3 Å. Homogeneous, non-homogeneous, and local refinements were used to
calculate the final map, including the whole Fab fragment. The map region corresponding to the constant
764 region of the Fab was removed in ChimeraX, and a soft binary mask was calculated using Relion. The final
map was calculated using the local refinement procedure with a focused mask centered on the Fab 77-F_{ECTO}
766 fragment interface by adjusting the fulcrum coordinates.

768 ***Model building***

For the F_{ECTO}-Fab 77 structure, the obtained cryo-EM map was used to dock the previously published F X-ray structure (PDB ID: 5XYW (52)) using ChimeraX. Next, the antibody model was generated with an in-house implementation of ColabFold based on AlphaFold2 (100, 101). Once the models were positioned, manual model building was conducted in Coot 0.9.8.7, sourced from the CCP4 package (102, 103). An automatically sharpened and density-modified map from PHENIX ResolveEM (using only half-maps) was the basis for model building (104). A real-space refinement protocol followed manual model building in the PHENIX package, consisting of 10 macrocycles without any enforced restraints, and increased the number of Max iterations to 800 (105). Finally, water placement was carried out manually on a density-modified map. Water molecules were positioned where spherical density was visible at map RMSD > 5.0, no more than 2.7 Å from protein atoms. Interfaces were analyzed using ChimeraX and PISA server (106). Electrostatic maps, as well as the generation of F variants, were calculated in ChimeraX. Local map scales for F_{ECTO} were calculated in OccuPy (107).

F_{ECTO} in the post-fusion conformation was first generated using homology modeling using SWISS-MODEL software and manually rebuilt in Coot(108). Refinement and evaluation of the model was done as described above.

In the case of the F_{ECTO} fragment stabilized by Fab 77, the structure of F_{ECTO}-Fab 77 was fitted into the obtained map. Residues located within this map were retained, and portions of the model not encompassed by the map were removed. Subsequently, the remaining model underwent relaxation with Isolde (109), manual Coot adjustments, and PHENIX refinement.

788 ***Heat-Induced refolding of F_{ECTO}-Fab 77***

A 7.5 μM solution of F_{ECTO} in HBS containing 800 mM NaCl was combined with a 1.5-fold molar excess of Fab 77. This mixture was then diluted four-fold using 50 mM HEPES (pH 8.0), resulting in a final NaCl concentration of approximately 150 mM. The complex was allowed to form at room temperature over 4 hrs. A 15 μL aliquot of the formed complex was transferred to a PCR tube and subjected to heat treatment in a PCR thermocycler. The incubation times tested were 1, 5, 7.5, or 10 min at 50 °C and 1 or 5 min at 55°C. After incubation, the samples were rapidly cooled by placing the tube on ice for 5 min. Negative stain grids were then prepared using the described protocol.

The acquired data were processed using cryoSPARC 4.3. After motion correction and estimation of CTF values, particle picking was performed using the blob picker. Subsequent 2D classification was performed using the previously described deep 2D classification protocol to separate particles into distinct classes.

800 ***Sequence analysis***

Approximately 1400 MeV genomic sequences were obtained from the nucleotide NCBI database. CDS regions were manually annotated and curated to include only those between 400 and 600 amino acid residues in length with pairwise alignment scores greater than zero as compared to the F WT sequence (Uniprot: Q786F3). The resulting ~820 sequences were aligned using Clustal Omega, and the conservation score was computed using AL2CO(89). Conservation scores were placed on the 3D models of F_{ECTO}^{PRE} and F_{ECTO}^{POST} in ChimeraX using AL2CO. Sequence variants were determined using a Python script based on the multiple sequence alignment file.

808 ***Glycoproteomics sample preparation***

For glycoproteomics analysis, a SP3 sample preparation protocol was applied (110). Recombinant measles
810 F_{ECTO} was denatured in the buffer with 2% SDS, 200 mM Tris/HCl, 10 mM tris(2-carboxyethyl)phosphine,
pH 8.0, at 95 °C for 10 min followed with 30 min reduction at 37 °C for 30 min. Samples were next alkylated
812 by adding 40 mM iodoacetamide and incubated in the dark at room temperature for 45 min. 3 µg
recombinant F_{ECTO} was used for each protease digestion. Samples were split in half for parallel digestion
814 with chymotrypsin (Sigma) and alpha lytic protease (Sigma). Sera-Mag beads (GE Healthcare) were used
at a bead/protein ratio of 10:1 (wt/wt) for protein binding. Ethanol was added to the protein-beads mixture
816 reaching final concentration 80% to enhance binding. The mixture was incubated at RT for 10 min at 1000
r.p.m. in a ThermoMixer. The supernatant was removed and protein-bound-beads washed three times with
818 80% ethanol. Measles F_{ECTO} was digested on beads overnight at 37 °C in 25 µL 50 mM ammonium
bicarbonate at 1000 r.p.m in a ThermoMixer. The supernatant was taken for MS analysis.

820 ***Glycoproteomics LC-MS/MS measurements***

The experiments were performed as previously described (111) with minor modifications, as follows. For
822 each sample and protease digestion, approximately 50 ng of peptides were run by online reversed phase
chromatography on an Dionex UltiMate 3000 (Thermo Fisher Scientific) coupled to a Thermo Scientific
824 Orbitrap Fusion mass spectrometer. A Poroshell 120 EC C18 (50 cm × 75 µm, 2.7 µm, Agilent Technologies)
analytical column and a ReproSil-Pur C18 (2 cm × 100 µm, 3 µm, Dr. Maisch) trap column were used for
826 peptide separation. Duplicate samples were analyzed with two different mass spectrometry methods, using
identical LC-MS parameters and distinct fragmentation schemes. In one method, peptides were subjected to
828 Electron Transfer/Higher-Energy Collision Dissociation (HCD) fragmentation. In the other method, all
precursors were subjected to HCD fragmentation, with additional EThcD fragmentation triggered by the
830 presence of glycan reporter oxonium ions. A 90 min LC gradient from 0% to 44% acetonitrile was used to
separate peptides at a flow rate of 300 nl/min. Data was acquired in data-dependent mode. Orbitrap Fusion
832 parameters for the full scan MS spectra were as follows: a standard AGC target at 60 000 resolution, scan
range 350–2000 m/z, Orbitrap maximum injection time 50 ms. The ten most intense ions (2+ to 8+ ions)
834 were subjected to fragmentation. For the EThcD fragmentation scheme, the supplemental higher energy
collision dissociation energy was set at 27%. MS2 spectra were acquired at a resolution of 30,000 with an
836 AGC target of 800%, maximum injection time 250 ms, scan range 120–4000 m/z and dynamic exclusion of
16 s. For the triggered HCD-EThcD method, the LC gradient and MS1 scan parameters were identical. The
838 ten most intense ions (2+ to 8+) were subjected to HCD fragmentation with 30% normalized collision energy
from 120–4000 m/z at 30,000 resolution with an AGC target of 100% and a dynamic exclusion window of
840 16 s. Scans containing any of the following oxonium ions within 20 ppm were followed up with additional
EThcD fragmentation with 27% supplemental HCD fragmentation. The triggering reporter ions were:
842 Hex(1) (129.039; 145.0495; 163.0601), PHex(1) (243.0264; 405.0793), HexNAc(1) (138.055; 168.0655;
186.0761), Neu5Ac(1) (274.0921; 292.1027), Hex(1)HexNAc(1) (366.1395), HexNAc(2) (407.166),
844 dHex(1)Hex(1)HexNAc(1) (512.1974), and Hex(1)HexNAc(1)Neu5Ac(1) (657.2349). EThcD spectra were
acquired at a resolution of 30,000 with a normalized AGC target of 400%, maximum injection time 250 ms,
846 and scan range 120–4000 m/z.

Glycoproteomics data analysis

848 The acquired data was analysed using Byonic (v4.5.2) against a custom database of recombinant F_{ECTO} and
the proteases used in the experiment, searching for glycan modifications with 12/24 ppm search windows
850 for MS1/MS2, respectively. Up to ten missed cleavages were permitted using C-terminal cleavage at
F/Y/W/M/L for chymotrypsin, or T/A/S/V for alpha lytic protease. For N-linked analysis,
852 carbamidomethylation of cysteine was set as fixed modification, oxidation of methionine/tryptophan as
variable common 1, and hexose on tryptophan as variable rare 1. N-glycan modifications were set as variable
854 common 2, allowing up to max. 2 variable common and 1 rare modification per peptide. All N-linked glycan
databases from Byonic were merged into a single non-redundant list to be included in the database search.
856 All reported glycopeptides in the Byonic result files were manually inspected for quality of fragment
assignments (with scores ≥ 200). All glycopeptide identifications from both EThcD and HCDpdEThcD runs
858 were merged into a single non-redundant list per sequon. Glycans were classified based on HexNAc content
as truncated (≤ 2 HexNAc; < 3 Hex), paucimannose (2 HexNAc, 3 Hex), oligomannose (2 HexNAc; > 3
860 Hex), hybrid (3 HexNAc) or complex (> 3 HexNAc). Byonic search results were exported to mzIdentML
format to build a spectral library in Skyline (v22.2.0.312) and extract peak areas for individual glycoforms
862 from MS1 scans. The full database of variable N-linked glycan modifications from Byonic was manually
added to the Skyline project file in XML format. Reported peak areas were pooled based on the number of
864 HexNAc, Fuc or NeuAc residues to distinguish truncated, paucimannose, oligomannose, hybrid, and
complex glycosylation, or the degree of fucosylation and sialylation, respectively.

Statistical analysis

All data analysis and visualizations were conducted using a Python notebook integrating SciPy, Matplotlib,
868 Pandas, Seaborn, and Statannotations packages (112–114). Statistical significance was determined using the
Mann-Whitney test. For p-value annotations, the following symbols were used: 'ns' indicates $p \leq 1$,*
870 represents $0.01 < p \leq 0.05$,** signifies $0.001 < p \leq 0.01$, and *** stands for $0.0001 < p \leq 0.001$.

Chemicals and peptides

872 Chemicals and peptides used here were previously described in (53). The description is reported here with
minimal modification. *N*-(3-cyanophenyl)-2-phenylacetamide (also known as 3G) was commercially
874 acquired from ZereneX Molecular Limited (UK).

Peptides were purchased from CPC, Ltd. Bromoacetyl cholesterol and bismaleimide cholesterol
876 derivatives were custom-made by Charnwood Molecular Ltd. Dimethylsulfoxide (DMSO), tetrahydrofuran
(THF) and *N,N*-diisopropylethylamine (DIPEA) were purchased from Sigma Aldrich, and bismaleimide-
878 PEG₁₁ was from Quanta BioDesign. HPLC purification was performed on an 1100 Series Agilent HPLC
system equipped with a UV diode array detector and a fraction collector using a reverse phase (RP.)
880 Phenomenex Jupiter C4 LC column 300Å (150 x 21.2 mm, particle size 5 μ m). MALDI-TOF analysis was
performed on Bruker ultrafleXtreme MALDI-TOF-TOF instrument.

882

Acknowledgments

884 We thank J. S. Orange for his support. We thank Michael Norris for valuable discussions at project outset,
886 and Theresa Gewering and Haoyang Li for assisting with the model evaluation. We thank Tiziana F. Bovier

888 for technical assistance in viral rescue. We thank Marissa Acciani and Sharon Schendel for careful reading
of the manuscript and suggestions. We thank the cryo-EM facility of La Jolla Institute for Immunology for
890 assistance with data collection and acknowledge the GHR Foundation and private donors for support of
instrumentation.

892
Funding: This work was supported by the National Institutes of Health (NS105699, NS091263, and
894 AI176833) to MP, Swiss National Science Foundation Postdoc Mobility fellowships P2E3P3_195680
(DSZ) and P500PB_210992 (DSZ), Measles Virus Biobank ([https://ciri.ens-lyon.fr/teams/IbIV/measles-](https://ciri.ens-lyon.fr/teams/IbIV/measles-biobank)
896 [biobank](https://ciri.ens-lyon.fr/teams/IbIV/measles-biobank)), the Dutch Research Council NWO Gravitation 2013 BOO, Institute for Chemical Immunology
ICI 024.002.009 (to JS), and institutional funds of La Jolla Institute for Immunology (EOS).

898
Author contributions:

900 DSZ: Designed protein constructs, cloned and expressed proteins, designed and performed DSF and DLS
experiments, expressed and digested antibodies, recorded all negative stain and cryo-EM data, processed
902 and solved structures, performed the point mutation analysis, wrote the code for analysis, analyzed all data
present in the manuscript, prepared figures, and wrote the manuscript, RDM: Virological and cell biology
904 experimentation, data analysis, GN: Assisted with the F_{ECTO}-Fab complex screening, protein purification,
NS-EM, and DSF, GZ: Cell biology experimentation, and data analysis, KS: Data analysis, CL: In vivo
906 experimentation and data analysis, EBS: Viral sequencing and data interpretation, HMC: Assisted with
initial protein expression optimization and kinetic analysis, CH: Measured Biolayer interferometry for
908 F_{ECTO} and Fab, WP: Glycoproteomics analysis and interpretation, DP: Assisted with cloning, expression,
and purification of constructs, TCM: Assisted data curation and analysis, RDA: Assisted with the cryo-EM
910 data acquisition and maintained microscopes, BH: Reagents and result interpretation, CM: Virological
support and result interpretation, JS: Glycoproteomics analysis and interpretation, funding, ALG:
912 Supervised viral sequencing and data interpretation, KMH: Data analysis, kinetic measurements, manuscript
writing, and figure preparation, SN: In vivo experimentation, data analysis and interpretation, supervision,
914 manuscript writing, AM: Results analysis and interpretation, supervision, manuscript writing, MP: Designed
proteins and antibodies, virological experimentation, cell biological experimentation, results analysis and
916 interpretation, supervision, funding, manuscript writing, EOS: Results analysis and interpretation,
supervision, funding, manuscript writing.

918 **Competing interests:**
Colombia University has filed a provisional patent related to the 77 antibody [US 18/491,733, continuation-
920 in-part of PCT/US22/25619 (expired) which claimed priority to US 63/177,224 (expired)]. The inventors
are Matteo Porotto, Anne Moscona, Branka Horvat, and Cyrille Mathieu. The other authors declare that they
922 have no competing interests in relation to the work described in this manuscript.

Data availability
924 Structural models are deposited in the protein data bank (PDB, <https://www.rcsb.org/>). The PDB IDs are:
F_{ECTO}: 8UUP, F_{ECTO}-FIP-HRC: 8UUQ, F_{ECTO}-Fab77: 8UT2, F_{ECTO} post-fusion: 8UTF, Fab 77-stabilized
926 F_{ECTO} fragment: 9AT8. Cryo-EM maps are deposited in the EM Database (<https://www.emdataresource.org/>)
with the following IDs: F_{ECTO}: EMD-42593, F_{ECTO}-FIP-HRC: EMD-42595, F_{ECTO}-Fab77: EMD-42527,

928 F_{ECTO} post-fusion: EMD-42539, Fab 77-stabilized F_{ECTO} fragment (masked): EMD-43827, Fab 77-stabilized
930 F_{ECTO} fragment: EMD-43828. The raw LC-MS/MS files and glycopeptide identifications have been
932 deposited to the ProteomeXchange Consortium via the PRIDE partner repository with the dataset identifier
PXD050366. Post-publication, all research materials referenced in this study will be made available upon
reasonable request through Material Transfer Agreements (MTAs).

934

Supplementary material:


936 Figs. S1 to S12

Tables S1 to S5

938 Movie S1

References 1-116

940 MDAR Reproducibility Checklist




942

Figure 1. mAb 77 displays robust antiviral activity *in vitro* and *in vivo*.


944 A) Antiviral potency of mAb 77 (violet) in a viral entry assay to measure inhibition of infection in Vero
 946 cells expressing SLAM/CD150. The activity was compared to established MeV inhibitors, 3G
 948 (green; (51)) and HRC4 (blue; (53)). Values for IC_{50} and Hill slope were estimated using logistic
 950 regression. 3G: $IC_{50}=150.1\pm 16.2$ nM, Hills slope= 0.37 ± 0.01 , HRC4: $IC_{50}=1.17\pm 0.27$ nM, Hills
 952 slope= 0.62 ± 0.07 , mAb 77: $IC_{50}=0.034\pm 0.005$ nM, Hills slope= 0.52 ± 0.04 . Each point with an error
 954 bar shows the average of three separate biological tests, \pm the standard error. B) Antibody transfer
 experiment to assess *in vivo* protective efficacy of mAb 77. Cotton rats received intraperitoneal (IP)
 injections of 0.1 mg/kg or 1 mg/kg mAb 77 12 hours before challenge with MeV. Animals in the
 control group received PBS before the challenge. Values correspond to MeV titers in lung tissue
 collected four days post-infection. The line inside the box represents the median value. Significance
 was shown using the Mann-Whitney-Wilcoxon test. P-value annotation legend: ns (non-significant):
 $p \leq 1.00$, *: $0.01 < p \leq 0.05$, **: $0.001 < p \leq 0.01$, ***: $0.0001 < p \leq 0.001$.

956



958 **Figure 2. mAb 77 mirrors the action of the HRC4 inhibitor and stabilizes the extended state of F protein.**

960 (A) Schematic representation of the red blood cell (RBC) fusion assay conducted in HEK 293T cells
 962 expressing a chimeric HN-H receptor binding protein with MeV F protein. (1) Without fusion inhibitors, the
 964 HN-H binds sialic acid on the RBCs. The MeV H stalk region subsequently activates the F protein,
 966 facilitating its refolding to a fusion intermediate that anchors the fusion peptide in the RBC membrane,
 968 culminating in the fusion of RBC and HEK 293T membranes. (2) In the presence of Zanamivir, a small-
 970 molecule inhibitor that competitively binds the HN sialic acid receptor binding site, reversible binding of
 972 RBCs to HN is observed (2.1). Adding 3G locks the F protein in its pre-fusion conformation, resulting in
 974 only reversible binding of most RBCs to the HN-H (2.2). (3) The subsequent checkpoint is evaluated through
 976 combined administration of Zanamivir and ACK buffer. Zanamivir acts as described in (2), whereas ACK
 978 buffer induces lysis of RBCs (dashed line). At this checkpoint, fusion intermediates with anchored fusion
 peptides within RBC membranes, such as those stabilized by HRC4, resist Zanamivir-induced dissociation
 (left, 3.1) but are lysed in the presence of ACK buffer (right, 3.2). (4) At the last checkpoint, complete
 fusion of RBC and HEK 293T membranes is achieved. Here, ACK buffer addition has no impact on the
 fused RBCs (4.1). (B) Bar chart summarizing the results of a mechanistic assay comparing various known
 inhibitors and mAb 77. For each condition, cells were categorized based on their interaction with red
 blood cells (RBCs): reversibly bound (dark blue) in which RBCs were adhered only by chimeric H and
 could be removed by treatment with Zanamivir; irreversibly bound (pink) in which RBCs were initially
 attached by chimeric H, but subsequent F protein refolding anchored the fusion peptide in the RBC
 membrane, making RBC attachment insensitive to Zanamivir with RBC retained on the HEK 293T cell
 surface; and fused (light blue) in which RBCs underwent membrane fusion with HEK 293T cells
 expressing the fusion complex.



980

Figure 3. Cryo-EM structure of mAb 77 Fab fragment engaging *FECTO* at the base of the head domain.

982

A) Primary structure annotation of *FECTO*. Functional domains are delineated as color-coded rectangular regions: SP, Signal Peptide; FP, Fusion Peptide; HRN, N-terminal Heptad Repeat; DIII, Domain III; DI, Domain I; DII, Domain II; HRC, C-terminal Heptad Repeat; 2xST, Twin Strep-Tag II. White hexagons denote glycosylation sites within the F2 region. A black loop represents natural disulfide bonds. Black scissors indicate the furin cleavage site that divides the precursor F0 into F2 and F1 subunits. Arrows indicate the locations of two stabilizing mutations.

984

B) A 2.1-Å resolution map of *FECTO*, showing F1 (green) and F2 (gray) with low-resolution map overlay showing details included in the map (silhouette).

986

C) Ribbon representation of the 2.3-Å resolution structure of *FECTO* in the presence of fusion inhibitor peptide (FIP) with a low resolution map as a silhouette.

990

D) Domain description of *FECTO*, colored from N terminus to C terminus (red to purple), as in A).

992

E) A ribbon representation of *FECTO* in complex with three copies of Fab 77. The Fabs interact symmetrically with the lower section of the head domain in a cleft between domains I and II. The *FECTO* F1 chain is represented in green, the F2 chain in gray, the 77 Fab heavy variable domain (VH) in violet, and the light variable domain (VL) in pale pink. The cryo-EM map, delineated as a silhouette, also encompasses the masked-out region, including the constant light and heavy segments (CL and CH) of the


994

F) Close-up view of the interaction between F1 and F2 chains, showing residues W27, G37, V125, L123, Y54, S31, T55, S40, T57, R72, and CDR H-2.

G) Close-up view of the interaction between F1 and F2 chains, showing residues CDR H-1, CDR H-2, and CDR H-3.

H) Close-up view of the interaction between F1 and F2 chains, showing residues F1_A, CDR L-2, Q383, R436, S434, R435, Y49, Y107, D109, Y105, and W101.

996 Fab 77. F) CDR loops H1 and H2 of Fab 77 establish hydrogen bonds with three distinct F_{ECTO} polypeptide
chains: F2_A (light gray), F1_A (light green), and F1_B (dark green). The interacting residues on F_{ECTO} and Fab
998 77 are shown in the respective colors of their chains. Interface residues F1B 383, 384, and CRD-H1 32, 33
are omitted for better visibility. Dashed lines depict the selected hydrogen bonds. G) The VH region of Fab
1000 77 contributes the majority of interactions with F, and all three heavy chain complementarity-determining
regions (CDRs H1, H2, and H3) engage with the head domain. Only one CDR L2 from the VL domain
1002 contributes to the interaction. Black rectangles show regions enlarged in F) and H). H) The CDR H3 and L2
interact with only a single F_{ECTO} chain, F1_A. The interacting residues are highlighted in the color of the
1004 respective chains as in E). Dashed lines represent chosen hydrogen bonds; a solid line indicates a salt bridge.




1006

Figure 4. The post-fusion conformation of F_{ECTO} shows significant structural domain reconfiguration that facilitates membrane fusion.

1008


1010 A) Cryo-EM structure of F_{ECTO} in its post-fusion conformation revealing a structural rearrangement of the
 1012 HRN and HRC, forming a canonical post-fusion 6-helix bundle. F1 and F2 are in shades of blue and pink,
 1014 respectively. The cryo-EM map is displayed as a silhouette, with two notable glycosylation sites (N61 and
 1016 N67) indicated and visualized only at the map level. B) Domain-based coloring of F_{ECTO} in the post-fusion
 1018 conformation as in Fig. 3D. C) Global alignment comparison between F_{ECTO} in pre-fusion (depicted in white
 1020 with silhouette) and post-fusion (in domain color scheme) conformations. Optimal global alignment per
 1022 chain was attained by aligning F_{ECTO} on domain I (highlighted in light green). Regions that undergo
 1024 significant conformational changes are surrounded in boxes and shown in panels D and E. D) Domain III
 1026 undergoes the most dramatic shift between pre- and post-fusion, moving its center of mass over by 11 Å and
 1028 rotating by 52°. Most of the fold remains unchanged when local alignment is performed on the sequence
 region corresponding to the domain region, with the most notable changes seen in the HRN, which releases
 the fusion peptide and refolds from multiple disjointed α -helices and β -strands into an ~ 100 Å extended
 helix. The furin-containing loop is depicted as a dashed line. Scissors symbolize the furin cleavage site. E)
 Domain II undergoes a twisting motion during the refolding step. Only slight differences are observed in the
 fold after local alignment for the residue range corresponding to the domain. The C-terminal region of the
 domain undergoes the most significant change. The HRC changes direction by nearly 180° around residue
 G433. HRC in black and color corresponds to the pre-fusion and post-fusion structure, respectively. F)
 Mapping of residues comprising the mAb 77 epitope on both the pre- and post-fusion states of F_{ECTO} reveals
 displacement of the epitope in the post-fusion state that explains the lack of mAb 77 binding to F_{ECTO} in the
 post-fusion conformation.



1030

1032 **Figure 5. Structural analysis of MeV F sequence conservation and viral evolution assay reveals**
 1034 **consistent conservation across the protein.**

1036 A) Conservation map of the MeV F full-length (FL) primary sequence derived from over 830 F sequences
 1038 in the NCBI protein database. The sequences were aligned using Clustal Omega(88), and the AL2CO
 1040 algorithm(89) was used to calculate the conservation score. MeV F demonstrates uniform sequence
 1042 conservation, with only two regions having lower conservation: the signal peptide and the cytoplasmic tail,
 1044 which are highlighted by black lines at the top of the plot. B) Mapping the AL2CO score onto the tertiary
 pre- and post-fusion structure of F_{ECTO} shows no conservation hotspots. In general, less exposed residues
 show higher sequence conservation compared to solvent-exposed residues. C) Most residues forming the
 mAb 77 epitope demonstrate high sequence conservation (light gray), but G37 and R437 (shown in shades
 of yellow) have been found in natural variants. D) Cell-based fusion inhibition assay to examine the impact
 of G37R and R436K mutations on mAb 77 binding affinity. The R436K mutation is common but has
 minimal influence on inhibition of antibody-mediated fusion. Conversely, the rarer G37R mutation could
 evade fusion inhibition by mAb 77.



1046

Figure 6. Cryo-EM to elucidate mAb 77 mechanism of action.

1048 A) 2D classes show conformational heterogeneity in the F_{ECTO} -Fab77 dataset. Using an extensive 2D
 1050 2D classification procedure, we could isolate 2D classes that constituted less than 1% of the dataset. The
 1052 leftmost panel, Panel 1, shows a 2D projection of the final volume of F_{ECTO} -Fab77, followed by classes
 1054 that depict intermediate refolding steps during Fab77-induced F_{ECTO} refolding. Panel 2 shows a refolding
 1056 intermediate, clearly showing a missing density corresponding to the HRN domain and a lack of density
 1058 between Fab77-bound domain II (DII, cyan) and domain I (DI, light green) of neighboring protomers.
 1060 Panel 3 shows a conformational state with protomer separation, which finally leads to a stabilized F
 1062 fragment (domains I and II) by Fab77 in Panel 4. The upper and lower circles correspond to the
 1064 projection and annotation based on the projection, respectively. Colors correspond to the domains:
 purple Fab77, light green domain I, dark green domain II, and orange HRN. Scale bars correspond to
 100 Å (first three classes) and 50 Å (last class). F2 was omitted from the annotated image for clarity.

B) Cryo-EM 2D class averages of Fab 77 stabilizing a fragment of F_{ECTO} .

C) Approximately 3.6 Å resolution density map of the Fab 77- F_{ECTO} fragment superimposed on the trimeric
 F_{ECTO} -Fab 77 complex. A zoomed-in view of the corresponding density associated with only a stabilized
 portion of F_{ECTO} is shown on the right. The interaction between Fab 77 and F_{ECTO} maintains stabilization
 of the previously characterized epitope to inhibit further refolding. Domain coloring follows the scheme
 presented in Figure 3. The left map was Gaussian blurred to 1.5 standard deviations to simplify
 visualization. Residues corresponding to the F_{ECTO} fragment are indicated.

1066 D) The proposed mechanism of action for mAb 77 depicts the observed populations of F_{ECTO}-Fab 77
1068 complexes across the reported experiments. Numbers for each stage of refolding correspond to those in
panel A.

1070 **References and notes**

- 1072 1. S. L. Katz, A. R. Hinman, Summary and conclusions: measles elimination meeting, 16-17 March 2000. *J. Infect. Dis.* **189 Suppl 1**, S43-7 (2004).
- 1074 2. A. P. Fiebelkorn, S. B. Redd, P. A. Gastañaduy, N. Clemmons, P. A. Rota, J. S. Rota, W. J. Bellini, G. S. Wallace, A comparison of postelimination measles epidemiology in the United States, 2009-2014 versus 2001-2008. *J. Pediatric Infect. Dis. Soc.* **6**, 40–48 (2017).
- 1076 3. P. A. Gastañaduy, S. B. Redd, A. P. Fiebelkorn, J. S. Rota, P. A. Rota, W. J. Bellini, J. F. Seward, G. S. Wallace, Measles—United States, January 1–May 23, 2014. *Am. J. Transplant* **14**, 1937–1940 (2014).
- 1078 4. M.-M. A. Fill, D. Sweat, H. Morrow, A. Haushalter, J. C. Martin, T. Zerwekh, T. Chakraverty, J. Kmet, K. Morris, K. Moore, M. Kainer, R. Murphree, J. R. Dunn, W. Schaffner, T. F. Jones, Notes from the Field: Measles Outbreak of Unknown Source - Shelby County, Tennessee, April-May 2016. *MMWR Morb. Mortal. Wkly. Rep.* **65**, 1039–1040 (2016).
- 1080 5. W. Orenstein, K. Seib, Mounting a good offense against measles. *N. Engl. J. Med.* **371**, 1661–1663 (2014).
- 1082 6. V. K. Phadke, R. A. Bednarczyk, D. A. Salmon, S. B. Omer, Association Between Vaccine Refusal and Vaccine-Preventable Diseases in the United States: A Review of Measles and Pertussis. *JAMA* **315**, 1149–1158 (2016).
- 1084 7. Nearly 40 million children are dangerously susceptible to growing measles threat, *CDC* (2022). <https://www.cdc.gov/media/releases/2022/p1123-measles-threat.html>.
- 1086 8. A 30-fold rise of measles cases in 2023 in the WHO European Region warrants urgent action. <https://www.who.int/europe/news/item/14-12-2023-a-30-fold-rise-of-measles-cases-in-2023-in-the-who-european-region-warrants-urgent-action>.
- 1090 9. K. Bochennek, R. Allwinn, R. Langer, M. Becker, O. T. Keppler, T. Klingebiel, T. Lehrnbecher, Differential loss of humoral immunity against measles, mumps, rubella and varicella-zoster virus in children treated for cancer. *Vaccine* **32**, 3357–3361 (2014).
- 1092 10. C. I. Paules, H. D. Marston, A. S. Fauci, Measles in 2019 - Going Backward. *N. Engl. J. Med.* **380**, 2185–2187 (2019).
- 1094 11. A. Fox, T. M. Hung, H. Wertheim, L. N. M. Hoa, A. Vincent, B. Lang, P. Waters, N. H. Ha, N. V. Trung, J. Farrar, N. Van Kinh, P. Horby, Acute measles encephalitis in partially vaccinated adults. *PLoS One* **8**, e71671 (2013).
- 1098 12. G. A. Poland, R. M. Jacobson, The re-emergence of measles in developed countries: time to develop the next-generation measles vaccines? *Vaccine* **30**, 103–104 (2012).
- 1100 13. J. A. Whitaker, T. D. Shanafelt, G. A. Poland, N. E. Kay, Room for improvement: immunizations for patients with monoclonal B-cell lymphocytosis or chronic lymphocytic leukemia. *Clin. Adv. Hematol. Oncol.* **12**, 440–450 (2014).
- 1102 14. A. Schuchat, A. P. Fiebelkorn, W. Bellini, Measles in the United States since the Millennium: Perils and Progress in the Postelimination Era. *Microbiol Spectr* **4** (2016).
- 1104
- 1106

- 1108 15. S. Bhattacharyya, M. J. Ferrari, Age-specific mixing generates transient outbreak risk following
critical-level vaccination. *Epidemiol. Infect.* **145**, 12–22 (2017).
- 1110 16. M. S. Gallone, C. Germinario, A. Larocca, S. Tafuri, Long time immunogenicity of measles vaccine in
the vaccination era: An open question. *Hum. Vaccin. Immunother.* **13**, 117–119 (2017).
- 1112 17. S. B. Sowers, J. S. Rota, C. J. Hickman, S. Mercader, S. Redd, R. J. McNall, N. Williams, M. McGrew,
M. L. Walls, P. A. Rota, W. J. Bellini, High Concentrations of Measles Neutralizing Antibodies and
1114 High-Avidity Measles IgG Accurately Identify Measles Reinfection Cases. *Clin. Vaccine Immunol.* **23**,
707–716 (2016).
- 1116 18. R. Seither, O. B. Yusuf, D. Dramann, K. Calhoun, A. Mugerwa-Kasujja, C. L. Knighton, Coverage with
selected vaccines and exemption from school vaccine requirements among children in kindergarten —
United States, 2022–23 school year. *MMWR Morb. Mortal. Wkly. Rep.* **72**, 1217–1224 (2023).
- 1118 19. J. F. Seward, W. A. Orenstein, Editorial commentary: A rare event: a measles outbreak in a population
1120 with high 2-dose measles vaccine coverage, *Clinical infectious diseases: an official publication of the
Infectious Diseases Society of America.* **55** (2012)pp. 403–405.
- 1122 20. G. De Serres, N. Boulianne, F. Defay, N. Brousseau, M. Benoît, S. Lacoursière, F. Guillemette, J. Soto,
M. Ouakki, B. J. Ward, D. M. Skowronski, Higher risk of measles when the first dose of a 2-dose
1124 schedule of measles vaccine is given at 12-14 months versus 15 months of age. *Clin. Infect. Dis.* **55**,
394–402 (2012).
- 1126 21. I. H. Haralambieva, I. G. Ovsyannikova, M. O’Byrne, V. S. Pankratz, R. M. Jacobson, G. A. Poland, A
large observational study to concurrently assess persistence of measles specific B-cell and T-cell
immunity in individuals following two doses of MMR vaccine. *Vaccine* **29**, 4485–4491 (2011).
- 1128 22. C.-J. Chen, P.-I. Lee, Y.-C. Hsieh, P.-Y. Chen, Y.-H. Ho, C.-J. Chang, D.-P. Liu, F.-Y. Chang, C.-H.
1130 Chiu, Y.-C. Huang, C.-Y. Lee, T.-Y. Lin, Waning population immunity to measles in Taiwan. *Vaccine*
30, 6721–6727 (2012).
- 1132 23. M. Kontio, S. Jokinen, M. Paunio, H. Peltola, I. Davidkin, Waning antibody levels and avidity:
implications for MMR vaccine-induced protection. *J. Infect. Dis.* **206**, 1542–1548 (2012).
- 1134 24. I. H. Haralambieva, R. B. Kennedy, I. G. Ovsyannikova, J. A. Whitaker, G. A. Poland, Variability in
Humoral Immunity to Measles Vaccine: New Developments. *Trends Mol. Med.* **21**, 789–801 (2015).
- 1136 25. J. W. Glasser, Z. Feng, S. B. Omer, P. J. Smith, L. E. Rodewald, The effect of heterogeneity in uptake
of the measles, mumps, and rubella vaccine on the potential for outbreaks of measles: a modelling
study. *Lancet Infect. Dis.* **16**, 599–605 (2016).
- 1138 26. S. Nyathi, H. C. Karpel, K. L. Sainani, Y. Maldonado, P. J. Hotez, E. Bendavid, N. C. Lo, The 2016
1140 California policy to eliminate nonmedical vaccine exemptions and changes in vaccine coverage: An
empirical policy analysis. *PLoS Med.* **16**, e1002994 (2019).
- 1142 27. M. J. Mina, T. Kula, Y. Leng, M. Li, R. D. de Vries, M. Knip, H. Siljander, M. Rewers, D. F. Choy, M.
S. Wilson, H. B. Larman, A. N. Nelson, D. E. Griffin, R. L. de Swart, S. J. Elledge, Measles virus
1144 infection diminishes preexisting antibodies that offer protection from other pathogens. *Science* **366**,
599–606 (2019).

- 1146 28. V. N. Petrova, B. Sawatsky, A. X. Han, B. M. Laksono, L. Walz, E. Parker, K. Pieper, C. A. Anderson,
1148 R. D. de Vries, A. Lanzavecchia, P. Kellam, V. von Messling, R. L. de Swart, C. A. Russell, Incomplete
genetic reconstitution of B cell pools contributes to prolonged immunosuppression after measles. *Sci Immunol* **4**, eaay6125 (2019).
- 1150 29. M. Ferren, B. Horvat, C. Mathieu, Measles Encephalitis: Towards New Therapeutics. *Viruses* **11**
(2019).
- 1152 30. P. A. Rota, W. J. Moss, M. Takeda, R. L. de Swart, K. M. Thompson, J. L. Goodson, Measles. *Nat. Rev. Dis. Primers* **2**, 16049 (2016).
- 1154 31. M. A. Brindley, S. Chaudhury, R. K. Plemper, Measles virus glycoprotein complexes preassemble
intracellularly and relax during transport to the cell surface in preparation for fusion. *J. Virol.* **89**, 1230–
1241 (2015).
- 1156 32. R. L. de Swart, S. Yüksel, A. D. M. E. Osterhaus, Relative contributions of measles virus
1158 hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. *J. Virol.* **79**, 11547–
11551 (2005).
- 1160 33. M. A. Muñoz-Alía, J. M. Casasnovas, M. L. Celma, J. Carabaña, P. B. Liton, R. Fernandez-Muñoz,
Measles Virus Hemagglutinin epitopes immunogenic in natural infection and vaccination are targeted
by broad or genotype-specific neutralizing monoclonal antibodies. *Virus Res.* **236**, 30–43 (2017).
- 1162 34. R. L. de Swart, S. Yüksel, C. N. Langerijs, C. P. Muller, A. D. M. E. Osterhaus, Depletion of measles
1164 virus glycoprotein-specific antibodies from human sera reveals genotype-specific neutralizing
antibodies. *J. Gen. Virol.* **90**, 2982–2989 (2009).
- 1166 35. C. Richardson, D. Hull, P. Greer, K. Hasel, A. Berkovich, G. Englund, W. Bellini, B. Rima, R.
Lazzarini, The nucleotide sequence of the mRNA encoding the fusion protein of measles virus
1168 (Edmonston strain): a comparison of fusion proteins from several different paramyxoviruses. *Virology*
155, 508–523 (1986).
- 1170 36. Y. Yanagi, M. Takeda, S. Ohno, T. Hashiguchi, Measles virus receptors. *Curr. Top. Microbiol. Immunol.*
329, 13–30 (2009).
- 1172 37. T. Hashiguchi, K. Maenaka, Y. Yanagi, Measles virus hemagglutinin: structural insights into cell entry
and measles vaccine. *Front. Microbiol.* **2**, 247 (2011).
- 1174 38. H. Tatsuo, N. Ono, K. Tanaka, Y. Yanagi, SLAM (CDw150) is a cellular receptor for measles virus.
Nature **406**, 893–897 (2000).
- 1176 39. M. D. Mühlebach, M. Mateo, P. L. Sinn, S. Prüfer, K. M. Uhlig, V. H. J. Leonard, C. K. Navaratnarajah,
M. Frenzke, X. X. Wong, B. Sawatsky, S. Ramachandran, P. B. McCray Jr, K. Cichutek, V. von
1178 Messling, M. Lopez, R. Cattaneo, Adherens junction protein nectin-4 is the epithelial receptor for
measles virus. *Nature* **480**, 530–533 (2011).
- 1180 40. R. S. Noyce, D. G. Bondre, M. N. Ha, L.-T. Lin, G. Sisson, M.-S. Tsao, C. D. Richardson, Tumor cell
marker PVRL4 (nectin 4) is an epithelial cell receptor for measles virus. *PLoS Pathog.* **7**, e1002240
(2011).

- 1182 41. H. S. Yin, R. G. Paterson, X. Wen, R. A. Lamb, T. S. Jardetzky, “Structure of the uncleaved ectodomain
of the paramyxovirus (hPIV3) fusion protein” (PNAS, 2005);
1184 <https://doi.org/10.1073/pnas.0503989102>.
42. R. A. Lamb, R. G. Paterson, T. S. Jardetzky, Paramyxovirus membrane fusion: lessons from the F and
1186 HN atomic structures. *Virology* **344**, 30–37 (2006).
43. G. B. E. Stewart-Jones, G.-Y. Chuang, K. Xu, T. Zhou, P. Acharya, Y. Tsybovsky, L. Ou, B. Zhang, B.
1188 Fernandez-Rodriguez, V. Gilardi, C. Silacci-Fregni, M. Beltramello, U. Baxa, A. Druz, W.-P. Kong, P.
V. Thomas, Y. Yang, K. E. Foulds, J.-P. Todd, H. Wei, A. M. Salazar, D. G. Scorpio, B. Carragher, C.
1190 S. Potter, D. Corti, J. R. Mascola, A. Lanzavecchia, P. D. Kwong, Structure-based design of a
quadrivalent fusion glycoprotein vaccine for human parainfluenza virus types 1–4. *Proceedings of the
1192 National Academy of Sciences* **115**, 12265–12270 (2018).
44. S. C. Harrison, Viral membrane fusion. *Nat. Struct. Mol. Biol.* **15**, 690–698 (2008).
- 1194 45. A. Chang, R. E. Dutch, Paramyxovirus fusion and entry: multiple paths to a common end. *Viruses* **4**,
613–636 (2012).
- 1196 46. R. K. Plemper, M. A. Brindley, R. M. Iorio, Structural and mechanistic studies of measles virus
illuminate paramyxovirus entry. *PLoS Pathog.* **7**, e1002058 (2011).
- 1198 47. J. M. White, S. E. Delos, M. Brecher, K. Schornberg, Structures and mechanisms of viral membrane
fusion proteins: multiple variations on a common theme. *Crit. Rev. Biochem. Mol. Biol.* **43**, 189–219
1200 (2008).
48. A. Sapir, O. Avinoam, B. Podbilewicz, L. V. Chernomordik, Viral and developmental cell fusion
1202 mechanisms: conservation and divergence. *Dev. Cell* **14**, 11–21 (2008).
49. C. Mathieu, M. Ferren, O. Harder, F. T. Bovier, T. C. Marcink, C. Predella, F. Angius, J. Drew-Bear, N.
1204 V. Dorrello, A. L. Greninger, A. Moscona, S. Niewiesk, B. Horvat, M. Porotto, Single-chain variable
fragment antibody constructs neutralize measles virus infection in vitro and in vivo. *Cell. Mol.
1206 Immunol.* **18**, 1835–1837 (2021).
50. E. Malvoisin, F. Wild, Contribution of measles virus fusion protein in protective immunity: anti-F
1208 monoclonal antibodies neutralize virus infectivity and protect mice against challenge. *J. Virol.* **64**,
5160–5162 (1990).
- 1210 51. A. Sun, A. Prussia, W. Zhan, E. E. Murray, J. Doyle, L.-T. Cheng, J.-J. Yoon, E. V. Radchenko, V. A.
Palyulin, R. W. Compans, D. C. Liotta, R. K. Plemper, J. P. Snyder, Nonpeptide inhibitors of measles
1212 virus entry. *J. Med. Chem.* **49**, 5080–5092 (2006).
- 1214 52. T. Hashiguchi, Y. Fukuda, R. Matsuoka, D. Kuroda, M. Kubota, Y. Shirogane, S. Watanabe, K.
Tsumoto, D. Kohda, R. K. Plemper, Y. Yanagi, Structures of the prefusion form of measles virus fusion
protein in complex with inhibitors. *Proc. Natl. Acad. Sci. U. S. A.* **115**, 2496–2501 (2018).
- 1216 53. F. T. Bovier, K. Rybkina, S. Biswas, O. Harder, T. C. Marcink, S. Niewiesk, A. Moscona, C. A. Alabi,
M. Porotto, Inhibition of Measles Viral Fusion Is Enhanced by Targeting Multiple Domains of the
1218 Fusion Protein. *ACS Nano* **15**, 12794–12803 (2021).

- 1220 54. S. Niewiesk, P.-G. Germann, Development of neutralizing antibodies correlates with resolution of interstitial pneumonia after measles virus infection in cotton rats. *J. Exp. Anim. Sci.* **40**, 201–210 (2000).
- 1222 55. S. Niewiesk, Cotton rats (*Sigmodon hispidus*): an animal model to study the pathogenesis of measles virus infection. *Immunol. Lett.* **65**, 47–50 (1999).
- 1224 56. C. K. Navaratnarajah, S. Kumar, A. Generous, S. Apte-Sengupta, M. Mateo, R. Cattaneo, The measles virus hemagglutinin stalk: structures and functions of the central fusion activation and membrane-proximal segments. *J. Virol.* **88**, 6158–6167 (2014).
- 1226 57. P. Plattet, L. Alves, M. Herren, H. C. Aguilar, Measles Virus Fusion Protein: Structure, Function and Inhibition. *Viruses* **8**, 112 (2016).
- 1228 58. Y. H. Kim, J. E. Donald, G. Grigoryan, G. P. Leser, A. Y. Fadeev, R. A. Lamb, W. F. DeGrado, Capture and imaging of a prehairpin fusion intermediate of the paramyxovirus PIV5. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 20992–20997 (2011).
- 1230 59. A. Talekar, A. Moscona, M. Porotto, Measles virus fusion machinery activated by sialic acid binding globular domain. *J. Virol.* **87**, 13619–13627 (2013).
- 1232 60. E. M. Jurgens, C. Mathieu, L. M. Palermo, D. Hardie, B. Horvat, A. Moscona, M. Porotto, Measles fusion machinery is dysregulated in neuropathogenic variants. *MBio* **6** (2015).
- 1234 61. C. D. Richardson, A. Scheid, P. W. Choppin, Specific inhibition of paramyxovirus and myxovirus replication by oligopeptides with amino acid sequences similar to those at the N-termini of the F1 or HA2 viral polypeptides. *Virology* **105**, 205–222 (1980).
- 1236 62. F. Angius, H. Smuts, K. Rybkina, D. Stelitano, B. Eley, J. Wilmshurst, M. Ferren, A. Lalande, C. Mathieu, A. Moscona, B. Horvat, T. Hashiguchi, M. Porotto, D. Hardie, Analysis of a Subacute Sclerosing Panencephalitis Genotype B3 Virus from the 2009-2010 South African Measles Epidemic Shows That Hyperfusogenic F Proteins Contribute to Measles Virus Infection in the Brain. *J. Virol.* **93** (2019).
- 1240 63. C. Mathieu, F. T. Bovier, M. Ferren, N. A. P. Lieberman, C. Predella, A. Lalande, V. Peddu, M. J. Lin, A. Addetia, A. Patel, V. Outlaw, B. Corneo, N. V. Dorrello, T. Briese, D. Hardie, B. Horvat, A. Moscona, A. L. Greninger, M. Porotto, Molecular Features of the Measles Virus Viral Fusion Complex That Favor Infection and Spread in the Brain. *MBio* **12**, e0079921 (2021).
- 1242 64. M. N. Ha, S. Delpout, R. S. Noyce, G. Sisson, K. M. Black, L.-T. Lin, D. Bilimoria, R. K. Plemper, G. G. Privé, C. D. Richardson, Mutations in the Fusion Protein of Measles Virus That Confer Resistance to the Membrane Fusion Inhibitors Carbobenzoxy-d-Phe-l-Phe-Gly and 4-Nitro-2-Phenylacetyl Amino-Benzamide. *J. Virol.* **91** (2017).
- 1244 65. K. Swanson, X. Wen, G. P. Leser, R. G. Paterson, R. A. Lamb, T. S. Jardetzky, Structure of the Newcastle disease virus F protein in the post-fusion conformation. *Virology* **402**, 372–379 (2010).
- 1246 66. A. J. May, K. R. Pothula, K. Janowska, P. Acharya, Structures of Langya Virus Fusion Protein Ectodomain in Pre- and Postfusion Conformation. *J. Virol.* **97**, e0043323 (2023).
- 1248
- 1250
- 1252
- 1254

- 1256 67. L. Chen, J. J. Gorman, J. McKimm-Breschkin, L. J. Lawrence, P. A. Tulloch, B. J. Smith, P. M. Colman,
1258 M. C. Lawrence, The structure of the fusion glycoprotein of Newcastle disease virus suggests a novel
paradigm for the molecular mechanism of membrane fusion. *Structure* **9**, 255–266 (2001).
- 1260 68. P. O. Byrne, B. E. Fisher, D. R. Ambrozak, E. G. Blade, Y. Tsybovsky, B. S. Graham, J. S. McLellan,
R. J. Loomis, Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein.
Nat. Commun. **14**, 1494 (2023).
- 1262 69. T. A. Poor, L. M. Jones, A. Sood, G. P. Leser, M. D. Plasencia, D. L. Rempel, T. S. Jardetzky, R. J.
1264 Woods, M. L. Gross, R. A. Lamb, Probing the paramyxovirus fusion (F) protein-refolding event from
pre- to postfusion by oxidative footprinting. *Proc. Natl. Acad. Sci. U. S. A.* **111**, E2596–605 (2014).
- 1266 70. M. A. Riddell, J. S. Rota, P. A. Rota, Review of the temporal and geographical distribution of measles
virus genotypes in the prevaccine and postvaccine eras. *Viol. J.* **2**, 87 (2005).
- 1268 71. P. A. Rota, W. J. Bellini, Update on the global distribution of genotypes of wild type measles viruses.
J. Infect. Dis. **187 Suppl 1**, S270–6 (2003).
- 1270 72. Nomenclature for describing the genetic characteristics of wild-type measles viruses (update). Part I.
Wkly. Epidemiol. Rec. **76**, 242–247 (2001).
- 1272 73. Genetic analysis of measles virus (2022). <https://www.cdc.gov/measles/lab-tools/genetic-analysis.html>.
- 1274 74. R. D. de Vries, S. McQuaid, G. van Amerongen, S. Yüksel, R. J. Verburgh, A. D. M. E. Osterhaus, W.
P. Duprex, R. L. de Swart, Measles immune suppression: lessons from the macaque model. *PLoS*
Pathog. **8**, e1002885 (2012).
- 1276 75. H. V. Dang, Y.-P. Chan, Y.-J. Park, J. Snijder, S. C. Da Silva, B. Vu, L. Yan, Y.-R. Feng, B. Rockx, T.
1278 W. Geisbert, C. E. Mire, C. C. Broder, D. Veelsler, An antibody against the F glycoprotein inhibits Nipah
and Hendra virus infections. *Nat. Struct. Mol. Biol.* **26**, 980–987 (2019).
- 1280 76. V. A. Avanzato, K. Y. Oguntuyo, M. Escalera-Zamudio, B. Gutierrez, M. Golden, S. L. Kosakovsky
Pond, R. Pryce, T. S. Walter, J. Seow, K. J. Doores, O. G. Pybus, V. J. Munster, B. Lee, T. A. Bowden,
1282 A structural basis for antibody-mediated neutralization of Nipah virus reveals a site of vulnerability at
the fusion glycoprotein apex. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 25057–25067 (2019).
- 1284 77. H. V. Dang, R. W. Cross, V. Borisevich, Z. A. Bornholdt, B. R. West, Y.-P. Chan, C. E. Mire, S. C. Da
1286 Silva, A. S. Dimitrov, L. Yan, M. Amaya, C. K. Navaratnarajah, L. Zeitlin, T. W. Geisbert, C. C. Broder,
D. Veelsler, Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion
glycoproteins. *Nat. Struct. Mol. Biol.* **28**, 426–434 (2021).
- 1288 78. T. C. Marcink, G. Zipursky, W. Cheng, K. Stearns, S. Stenglein, K. Golub, F. Cohen, F. Bovier, D.
Pfalmer, A. L. Greninger, M. Porotto, A. des Georges, A. Moscona, Subnanometer structure of an
1290 enveloped virus fusion complex on viral surface reveals new entry mechanisms. *Sci Adv* **9**, eade2727
(2023).
- 1292 79. M. Cabán, J. V. Rodarte, M. Bibby, M. D. Gray, J. J. Taylor, M. Pancera, J. Boonyaratanakornkit, Cross-
protective antibodies against common endemic respiratory viruses. *Nat. Commun.* **14**, 798 (2023).

- 1294 80. L. L. Hammitt, R. Dagan, Y. Yuan, M. Baca Cots, M. Bosheva, S. A. Madhi, W. J. Muller, H. J. Zar, D.
Brooks, A. Grenham, U. Wählby Hamrén, V. S. Mankad, P. Ren, T. Takas, M. E. Abram, A. Leach, M.
1296 P. Griffin, T. Villafana, MELODY Study Group, Nirsevimab for prevention of RSV in healthy late-
preterm and term infants. *N. Engl. J. Med.* **386**, 837–846 (2022).
- 1298 81. H. Wu, D. S. Pfarr, S. Johnson, Y. A. Brewah, R. M. Woods, N. K. Patel, W. I. White, J. F. Young, P. A.
Kiener, Development of motavizumab, an ultra-potent antibody for the prevention of respiratory
syncytial virus infection in the upper and lower respiratory tract. *J. Mol. Biol.* **368**, 652–665 (2007).
- 1300 82. Q. Zhu, J. S. McLellan, N. L. Kallewaard, N. D. Ulbrandt, S. Palaszynski, J. Zhang, B. Moldt, A. Khan,
C. Svabek, J. M. McAuliffe, D. Wrapp, N. K. Patel, K. E. Cook, B. W. M. Richter, P. C. Ryan, A. Q.
1302 Yuan, J. A. Suzich, A highly potent extended half-life antibody as a potential RSV vaccine surrogate
for all infants. *Sci. Transl. Med.* **9**, eaaj1928 (2017).
- 1304 83. O. Reynard, C. Gonzalez, C. Dumont, M. Iampietro, M. Ferren, S. Le Guellec, L. Laurie, C. Mathieu,
G. Carpentier, G. Roseau, F. T. Bovier, Y. Zhu, D. Le Penec, J. Montharu, A. Addetia, A. L. Greninger,
1306 C. A. Alabi, E. Brisebard, A. Moscona, L. Vecellio, M. Porotto, B. Horvat, Nebulized fusion inhibitory
peptide protects cynomolgus macaques from measles virus infection. *Nat. Commun.* **13**, 6439 (2022).
- 1308 84. C. Mathieu, D. Huey, E. Jurgens, J. C. Welsch, I. DeVito, A. Talekar, B. Horvat, S. Niewiesk, A.
Moscona, M. Porotto, Prevention of measles virus infection by intranasal delivery of fusion inhibitor
1310 peptides. *J. Virol.* **89**, 1143–1155 (2015).
- 1312 85. G. Frey, H. Peng, S. Rits-Volloch, M. Morelli, Y. Cheng, B. Chen, A fusion-intermediate state of HIV-
1 gp41 targeted by broadly neutralizing antibodies. *Proc. Natl. Acad. Sci. U. S. A.* **105**, 3739–3744
(2008).
- 1314 86. F. H. Niesen, H. Berglund, M. Vedadi, The use of differential scanning fluorimetry to detect ligand
interactions that promote protein stability. *Nat. Protoc.* **2**, 2212–2221 (2007).
- 1316 87. P. J. A. Cock, T. Antao, J. T. Chang, B. A. Chapman, C. J. Cox, A. Dalke, I. Friedberg, T. Hamelryck,
F. Kauff, B. Wilczynski, M. J. L. de Hoon, Biopython: freely available Python tools for computational
1318 molecular biology and bioinformatics. *Bioinformatics* **25**, 1422–1423 (2009).
88. F. Sievers, D. G. Higgins, Clustal omega. *Curr. Protoc. Bioinformatics* **48**, 3.13.1-3.13.16 (2014).
- 1320 89. J. Pei, N. V. Grishin, AL2CO: calculation of positional conservation in a protein sequence alignment.
Bioinformatics **17**, 700–712 (2001).
- 1322 90. Hunter, Matplotlib: A 2D Graphics Environment. **9**, 90–95 (2007).
91. M. Waskom, seaborn: statistical data visualization. *J. Open Source Softw.* **6**, 3021 (2021).
- 1324 92. T. D. Goddard, C. C. Huang, E. C. Meng, E. F. Pettersen, G. S. Couch, J. H. Morris, T. E. Ferrin, UCSF
ChimeraX: Meeting modern challenges in visualization and analysis. *Protein Sci.* **27**, 14–25 (2018).
- 1326 93. A. Punjani, J. L. Rubinstein, D. J. Fleet, M. A. Brubaker, cryoSPARC: algorithms for rapid
unsupervised cryo-EM structure determination. *Nat. Methods* **14**, 290–296 (2017).
- 1328 94. S. H. W. Scheres, RELION: implementation of a Bayesian approach to cryo-EM structure
determination. *J. Struct. Biol.* **180**, 519–530 (2012).

- 1330 95. D. Kimanius, L. Dong, G. Sharov, T. Nakane, S. H. W. Scheres, New tools for automated cryo-EM single-particle analysis in RELION-4.0. *Biochem. J* **478**, 4169–4185 (2021).
- 1332 96. D. Zyla, *Dzyla/Follow_Relion_gracefully: V4* (2023; <https://zenodo.org/record/7844516>).
- 1334 97. S. Q. Zheng, E. Palovcak, J.-P. Armache, K. A. Verba, Y. Cheng, D. A. Agard, MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. *Nat. Methods* **14**, 331–332 (2017).
- 1336 98. A. Rohou, N. Grigorieff, CTFFIND4: Fast and accurate defocus estimation from electron micrographs. *J. Struct. Biol.* **192**, 216–221 (2015).
- 1338 99. T. Bepler, A. Morin, M. Rapp, J. Brasch, L. Shapiro, A. J. Noble, B. Berger, Positive-unlabeled convolutional neural networks for particle picking in cryo-electron micrographs. *Nat. Methods* **16**, 1153–1160 (2019).
- 1340 100. M. Mirdita, K. Schütze, Y. Moriwaki, L. Heo, S. Ovchinnikov, M. Steinegger, ColabFold: making protein folding accessible to all. *Nat. Methods* **19**, 679–682 (2022).
- 1342 101. J. Jumper, R. Evans, A. Pritzel, T. Green, M. Figurnov, O. Ronneberger, K. Tunyasuvunakool, R. Bates, A. Žídek, A. Potapenko, A. Bridgland, C. Meyer, S. A. A. Kohl, A. J. Ballard, A. Cowie, B. Romera-Paredes, S. Nikolov, R. Jain, J. Adler, T. Back, S. Petersen, D. Reiman, E. Clancy, M. Zielinski, M. Steinegger, M. Pacholska, T. Berghammer, S. Bodenstein, D. Silver, O. Vinyals, A. W. Senior, K. Kavukcuoglu, P. Kohli, D. Hassabis, Highly accurate protein structure prediction with AlphaFold. *Nature* **596**, 583–589 (2021).
- 1344 102. P. Emsley, B. Lohkamp, W. G. Scott, K. Cowtan, Features and development of Coot. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 486–501 (2010).
- 1346 103. J. Agirre, M. Atanasova, H. Bagdonas, C. B. Ballard, A. Baslé, J. Beilsten-Edmands, R. J. Borges, D. G. Brown, J. J. Burgos-Mármol, J. M. Berrisford, P. S. Bond, I. Caballero, L. Catapano, G. Chojnowski, A. G. Cook, K. D. Cowtan, T. I. Croll, J. É. Debreczeni, N. E. Devenish, E. J. Dodson, T. R. Drevon, P. Emsley, G. Evans, P. R. Evans, M. Fando, J. Foadi, L. Fuentes-Montero, E. F. Garman, M. Gerstel, R. J. Gildea, K. Hatti, M. L. Hekkelman, P. Heuser, S. W. Hoh, M. A. Hough, H. T. Jenkins, E. Jiménez, R. P. Joosten, R. M. Keegan, N. Keep, E. B. Krissinel, P. Kolenko, O. Kovalevskiy, V. S. Lamzin, D. M. Lawson, A. A. Lebedev, A. G. W. Leslie, B. Lohkamp, F. Long, M. Malý, A. J. McCoy, S. J. McNicholas, A. Medina, C. Millán, J. W. Murray, G. N. Murshudov, R. A. Nicholls, M. E. M. Noble, R. Oeffner, N. S. Pannu, J. M. Parkhurst, N. Pearce, J. Pereira, A. Perrakis, H. R. Powell, R. J. Read, D. J. Rigden, W. Rochira, M. Sammito, F. Sánchez Rodríguez, G. M. Sheldrick, K. L. Shelley, F. Simkovic, A. J. Simpkin, P. Skubak, E. Sobolev, R. A. Steiner, K. Stevenson, I. Tews, J. M. H. Thomas, A. Thorn, J. T. Valls, V. Uski, I. Usón, A. Vagin, S. Velankar, M. Vollmar, H. Walden, D. Waterman, K. S. Wilson, M. D. Winn, G. Winter, M. Wojdyr, K. Yamashita, The CCP4 suite: integrative software for macromolecular crystallography. *Acta Crystallogr D Struct Biol* **79**, 449–461 (2023).
- 1348 104. T. C. Terwilliger, S. J. Ludtke, R. J. Read, P. D. Adams, P. V. Afonine, Improvement of cryo-EM maps by density modification. *Nat. Methods* **17**, 923–927 (2020).
- 1350 105. P. D. Adams, P. V. Afonine, G. Bunkóczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L.-W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger, P. H. Zwart, PHENIX: a comprehensive Python-

- 1370 based system for macromolecular structure solution. *Acta Crystallogr. D Biol. Crystallogr.* **66**, 213–
221 (2010).
- 1372 106. E. Krissinel, K. Henrick, “Detection of Protein Assemblies in Crystals” in *Computational Life
Sciences* (Springer Berlin Heidelberg, 2005), pp. 163–174.
- 1374 107. B. O. Forsberg, P. N. M. Shah, A. Burt, A robust normalized local filter to estimate compositional
heterogeneity directly from cryo-EM maps. *Nat. Commun.* **14**, 5802 (2023).
- 1376 108. N. Guex, M. C. Peitsch, T. Schwede, Automated comparative protein structure modeling with
SWISS-MODEL and Swiss-PdbViewer: a historical perspective. *Electrophoresis* **30 Suppl 1**, S162-73
1378 (2009).
109. T. I. Croll, ISOLDE: a physically realistic environment for model building into low-resolution
1380 electron-density maps. *Acta Crystallogr. D Struct. Biol.* **74**, 519–530 (2018).
110. C. S. Hughes, S. Moggridge, T. Müller, P. H. Sorensen, G. B. Morin, J. Krijgsveld, Single-pot, solid-
1382 phase-enhanced sample preparation for proteomics experiments. *Nat. Protoc.* **14**, 68–85 (2019).
111. W. Peng, V. Rayaprolu, A. D. Parvate, M. F. Pronker, S. Hui, D. Parekh, K. Shaffer, X. Yu, E. O.
1384 Sapphire, J. Snijder, Glycan shield of the ebolavirus envelope glycoprotein GP. *Commun. Biol.* **5**, 785
(2022).
112. P. Virtanen, R. Gommers, T. E. Oliphant, M. Haberland, T. Reddy, D. Cournapeau, E. Burovski, P.
1386 Peterson, W. Weckesser, J. Bright, S. J. van der Walt, M. Brett, J. Wilson, K. J. Millman, N. Mayorov,
1388 A. R. J. Nelson, E. Jones, R. Kern, E. Larson, C. J. Carey, Í. Polat, Y. Feng, E. W. Moore, J. VanderPlas,
D. Laxalde, J. Perktold, R. Cimrman, I. Henriksen, E. A. Quintero, C. R. Harris, A. M. Archibald, A.
1390 H. Ribeiro, F. Pedregosa, P. van Mulbregt, SciPy 1.0 Contributors, SciPy 1.0: fundamental algorithms
for scientific computing in Python. *Nat. Methods* **17**, 261–272 (2020).
113. W. Mc Kinney, Pandas: A foundational python library for data analysis and statistics (2011).
1392 [https://www.dlr.de/sc/portaldata/15/resources/dokumente/pyhpc2011/submissions/pyhpc2011_submis-
1394 sion_9.pdf](https://www.dlr.de/sc/portaldata/15/resources/dokumente/pyhpc2011/submissions/pyhpc2011_submission_9.pdf).
114. F. Charlier, M. Weber, D. Izak, E. Harkin, M. Magnus, J. Lalli, L. Fresnais, M. Chan, N. Markov, O.
1396 Amsalem, S. Proost, A. Krasoulis, getzze, S. Repplinger, *Trevismd/Statannotations: V0.5* (2022;
<https://zenodo.org/record/7213391>).
- 1398

1400

1402 Supplementary Materials for

1404 **A neutralizing antibody prevents post-fusion transition of measles fusion protein**

1406 Dawid S. Zyla¹, Roberta Della Marca^{2,3,4}, Gele Niemeyer^{1,5}, Gillian Zipursky^{2,3}, Kyle Stearns^{2,3}, Cameron
1408 Leedale⁶, Elizabeth B. Sobolik⁷, Heather Callaway^{1#}, Chitra Hariharan¹, Weiwei Peng^{8,9}, Diptiben Parekh¹,
1410 Tara C. Marcink^{2,3}, Ruben Diaz Avalos¹, Branka Horvat¹⁰, Cyrille Mathieu¹¹, Joost Snijder^{8,9}, Alexander L.
Greninger⁷, Kathryn M. Hastie¹, Stefan Niewiesk⁶, Anne Moscona^{2,3,12,13}, Matteo Porotto^{2,3,4*}, Erica
Ollmann Saphire^{1,14*}

1412 Corresponding authors: mp3509@columbia.edu and erica@lji.org

1414

The PDF file includes:

1416 Figs. S1 to S12



Tables S1 to S5

1418

Other Supplementary Materials for this manuscript include the following:

1420 Movie S1

Supplementary figures



1422

Figure S1. RBC fusion assay overview and non-normalized assay data.

1424


A) Detailed RBC fusion assay schematic related to Fig. 2A following steps described in the Methods section.

1426

B) Detailed plot from Fig. 2B showing the non-normalized average percentages (\pm std dev) and individual data points for reversibly bound, irreversibly bound, or fused RBCs following treatment with diluent

1428

(Mock), inhibitors, or mAb 77 (20-500 nM).



1430 **Figure S2. Biochemical analyses of F_{ECTO} and mAb 77 Fab complex formation.**

- 1432 A) The β -galactosidase complementation assay between cells expressing MeV H and F variants and cells
 1434 expressing the MeV receptor huCD150 showed that after an 18-hour incubation period, E455G and
 1436 E455G/E170G had 7.6-fold and 6.1-fold lower fusogenicity, respectively, compared to the wild-type
 (wt) F protein. Bars represent mean, and error bars correspond to standard error.
- B) A time-based thermal stability assay was performed on F variants expressed on cells by evaluating the
 binding of mAb77. Cells expressing F variants were incubated at 60 °C for varying periods ranging
 from 0 to 30 minutes. A higher percentage of mAb 77 epitope was observed in cells expressing E455G

1438 and E455G/E170G than those expressing wt F. The stability half-lives were 8.7 and 10.8 minutes for
1440 E455G and E455G/E170G, respectively, compared to 2.6 minutes for wt protein. Points correspond to
mean, and error bars show standard error.

1442 C) Purity of F_{ECTO} and Fab 77 verified using SDS-PAGE. F_{ECTO} exhibits a single band corresponding to
approximately 54 kDa (F1+F2) and 37 kDa under non-reducing (non-red) conditions and reducing
1444 conditions (red), respectively. Due to its high glycosylation, F2 appears as a smear at around 20 kDa.

1446 D) Negative stain electron microscopy (NS EM) 2D classes of F_{ECTO} in the pre-fusion conformation after
purification.


1448 E) Effect of buffer pH on F_{ECTO} apparent melting temperature (T_m^{app}). Five different pH values were
examined, with the resulting F_{ECTO} T_m^{app} values measured and depicted in the corresponding graphs. The
final plot shows the trend across the pH values.

1450 F) Effect of salt concentration on F_{ECTO} stability. F_{ECTO} was incubated in six salt concentrations (60 – 1460
mM) and the stability is expressed as T_m^{app} . The trend demonstrating the relationship between salt
concentration and F_{ECTO} stability is illustrated in the final graph.

1452 G) Bio-Layer interferometry (BLI) binding curves for F_{ECTO} and Fab 77 reveal high association ($3.48 \cdot 10^5$
 $M^{-1}s^{-1}$) and slow dissociation kinetics ($1.25 \cdot 10^{-4} s^{-1}$), with a calculated K_D of $3.61 \cdot 10^{-10} M$.


1454 H) Size exclusion profile of the F_{ECTO} and Fab 77 complex. The purple line signifies a 1:1 mixture of F_{ECTO}:
Fab 77, with a fully formed complex peak at approximately 11.7 ml and a Fab peak at 16.5 ml. The
1456 green line represents the F_{ECTO} elution profile.

1458



1460 **Figure S3** Representative micrographs for each dataset with particle picking from the final particle stack (left) and selected 2D classes (right).

1462 A) F_{ECTO} , B) F_{ECTO} -[FIP-HRC]₂-PEG₁₁, C) F_{ECTO} -Fab 77, D) F_{ECTO} in post-fusion conformation. Scale bar (left) for the micrographs corresponds to 500 Å. Red circles show particles locations that contributed to the final particle stack. The scale bar (right) corresponds to 150 Å.



1466

Figure S4 Final map quality, local resolution, FSC, and particle angular distribution for each recorded dataset.


1468

A) F_{ECTO}

1470 B) F_{ECTO}-[FIP-HRC]₂-PEG₁₁

C) F_{ECTO}-Fab 77

1472 D) F_{ECTO} in post-fusion conformation.



1474

Figure S5 Cryo-EM data processing for each recorded dataset as described in the Methods. The green highlight indicates selected classes.

1476

E) F_{ECTO}


1478

F) F_{ECTO}-[FIP-HRC]₂-PEG₁₁

G) F_{ECTO}-Fab 77

1480

H) F_{ECTO} in post-fusion conformation.




1482

Figure S6. Structure analysis and comparison of F_{ECTO} .

- 1484 A) Differences between disulfide-stabilized F_{ECTO} (X-ray), and native F_{ECTO} (cryo-EM). The graph shows
 1486 the $C\alpha$ root mean square deviation (RMSD) between the X-ray structures (F_{ECTO} APO: 5YXW, F_{ECTO}
 1488 FIP: 5YZD, F_{ECTO} AS-48: 5YZC) and the cryo-EM F_{ECTO} . Each model was globally aligned based on a
 single monomer (F1+F2), after which the RMSD was calculated between residues present in both
 structures. Regions with the highest RMSD include the loop 248-265 and the stalk region highlighted
 in B and C.
- 1490 B) The ribbon diagram presents the global alignment of the X-ray and cryo-EM models, as in C. Arrows
 indicated areas exhibiting high RMSD.
- 1492 C) Close-up view of the areas marked in D), with the starting and ending residues indicated. The color
 coding matches that in D).
- 1494 D) Application of local scaling to the F_{ECTO} -[FIP-HRC]₂-PEG₁₁ map using OccuPy. On the left, the relative
 1496 occupancy of the unsharpened map is shown, and on the right, an equalized map that enhances regions
 1498 with low occupancy or resolution, illustrating glycans (N29, N61, and N67), the furin-containing loop
 and the density from [FIP-HRC]₂-PEG₁₁. Color map corresponding to the calculated local scale, red
 indicating low values and blue indicating high values.
- 1500 E) The equalized map is presented at both low (on the left) and high (on the right) contour levels. Arrows
 1502 indicate locations of FIP and HRC. The density corresponding to FIP was clearly visible in the
 unequalized map, whereas the density associated with HRC only became apparent at the high contour
 level in the equalized map.

1504




1506 **Figure S7. Comparative analysis of the shape and dimensions of *FECTO* in its pre- and post-fusion conformations.**

1508 A) Final models for both *FECTO* conformations and their respective dimensions (top). The final map
 1510 projections (bottom) reveal differences in particle shapes between the two conformations when viewed
 from the side and top. The scale bar represents 100 Å.

1512 B) Visual representation of the domains, elucidating the changes in domain conformations and overall
 shape transitioning from the pre- to post-fusion state. The domains are color-coded consistently across
 1514 both models for ease of comparison.


1514 C) Glycosylation analysis of *FECTO*: MeV F has three glycosylation sites at positions N29, N61, and N67
 (hot pink). The observed glycosylation patterns from mass spectrometry correspond to the expected
 1516 glycosylation patterns obtained from the *Drosophila* S2 expression system. Specifically, the N29 site
 1518 was found to have a uniform high-mannose type of glycosylation, while N61 mostly and N67 uniformly
 had paucimannose type of glycosylation. The modeled glycosylation sites are shown for pre-fusion
 1520 *FECTO* (left, green/gray) and post-fusion *FECTO* (right, blue-dark pink). NAG: N-Acetylglucosamine,
 FUC: Fucose, BMA: beta-D-mannose.



1522 **Figure S8. Quantitative analysis of cell-surface expression, cell-surface staining and fusion inhibition of**
 1524 **F protein variants by mAb 77.**

- 1524 A) Western blot analysis using anti-HRC antibodies to detect F protein variants after 24h and 48h in cell-
 1526 surface biotinylation assays conducted at 32 °C and 37 °C.
- 1526 B) Bar graph representing the relative integrated band intensities derived from A). The data are normalized
 1528 with respect to the wt F protein band intensity at 24 h, 37 °C. Longer expression (48 h) led to higher
 1530 levels of F for all variants except R436G at 37 °C. Also, a change in charge (R436G) or charge reversal
 1532 (R436D) lowered the amount of protein detected on the surface.
- 1530 C) Cell surface staining of F protein variants after 48 h at 32 °C in the presence of mAb 77, adjusted for
 1532 average expression levels as determined from panel B. Dotted lines connect discrete data points for
 1534 clarity. The binding of mAb 77 to the R436K variant of F was only slightly lower than that for wt.
 Despite the lower expression of R436G, after normalizing expression levels binding of mAb 77 had
 enhanced higher recognition of this construct relative to wild type, albeit with much lower affinity.


- 1536 D) F protein variant fusion inhibition by mAb 77 was examined at 32 °C using the β -galactosidase
1538 complementation assay. Data are normalized to the highest signal per variant. Solid lines represent
1540 nonlinear regression logistic curves fit to the data, whereas dotted lines connect discrete data points for
ease of interpretation. Fit values were obtained from global fits to all data points with shared IC_{50} and
Hill slope wt: $IC_{50}=1.2\pm 0.3$ nM, slope= 0.73 ± 0.11 , R436K: $IC_{50}=0.58\pm 0.27$ nM, slope= 0.48 ± 0.08 ,
R436G: $IC_{50}=65.7\pm 41.7$ nM, slope= 0.12 ± 0.02 . Error bars represent standard error from 3 biological
replicates.
- 1542 E) As in panel D, but non-normalized data are shown to elucidate the relative magnitude of fusion activity
1544 among different F protein variants. Even in the absence of mAb77-induced inhibition, the G37R
mutation had only ~12% of the fusion capability seen for wt F, indicating that MeV harboring this F
variant would likely have lower propagation potential.
- 1546 F) Computational analysis of the impact of point mutations on the electrostatic surface potential maps of
1548 F_{ECTO} . The color scale represents electrostatic potential in volts, with red, white and blue indicating -10,
0, and +10, respectively. Arrows pinpoint the locations of mutations under investigation. The R436K
1550 mutation does not modify the local charge within the mAb 77 epitope on the F protein, which accounts
1552 for the wild-type-like performance of this variant in the mAb77 inhibition assay. In contrast, the R436G
mutation leads to a loss of charge, significantly reducing the binding and neutralization capacity of
1554 mAb77, although it does not prevent recognition of the F protein by mAb77. The introduction of a
charge reversal mutation, R436D, induces charge repulsion with Asp109 in the heavy chain CDR 3 of
1556 mAb 77, which is likely responsible for the complete lack of mAb 77 binding to this variant.
Furthermore, the G37R mutation may introduce steric hindrance within the indicated area, particularly
affecting interactions with Y54 in the heavy chain CDR 2 that could impact binding.



1558 **Figure S9. Structural and biophysical investigation of the effects of mAb 77 on FECTO.**

- 1560 A) Per residue RMSD analysis between FECTO-Fab 77 and FECTO structure. Two RMSD statistics per residue
 1562 were calculated based on all atoms in the residue (blue) and only between Cα (orange). Black dots
 1564 positioned on top of the lines indicate the locations of residues involved in the mAb 77 epitope. Dashed
 1566 lines represent the average all-atom (gray) and C-alpha atom (Cα, black) RMSD.
- B) The influence of Fab 77 binding is demonstrated through structural mapping of the Cα RMSD between
 two pre-fusion FECTO structures in complex with Fab 77 and FECTO alone. The intensifying red gradient
 indicates an increase in Cα RMSD, with arrows pinpointing the antibody-binding epitope presented in
 gray.

- 1568 C) Differential scanning fluorimetry (DSF) experiments with F_{ECTO} and complexes of F_{ECTO} with [FIP-
HRC]₂-PEG₁₁ and Fab 77. The thermal stability of F_{ECTO}, stabilized by two point mutations (E170G and
1570 E450G), had a T_m^{app} of 47.6 °C. The addition of [FIP-HRC]₂-PEG₁₁ enhanced the thermal stability to
56.7 °C, whereas the Fab 77 only slightly stabilized F_{ECTO}, raising the temperature to 51.6 °C.
- 1572 D) Temperature-resolved Dynamic Light Scattering (DLS) experiment with F_{ECTO} and Fab 77. The
experiment reveals the unique behavior of F_{ECTO} in the presence and absence of Fab 77. In the absence
1574 of Fab 77, F_{ECTO} undergoes a transition at 44.7 °C, which increases the particle radius concurrent with
increased temperature. The absence of a clear lag phase following triggering suggests that refolding and
aggregation occur simultaneously. However, when F_{ECTO} is bound by Fab 77, a distinct plateau phase
1576 emerges between approximately 50-65 °C, indicating stabilization of an intermediate refolding step. The
unfolding/aggregation behavior of Fab 77 alone and in the F_{ECTO}-Fab 77 complex is similar, starting
1578 above 63 °C. Due to experimental limitations, the Fab 77 trace is not fully resolved at temperatures
higher than 70 °C. Onset (10% of the total signal) is indicated by dashed lines.



1580

Figure S10. Time-resolved heating experiment with F_{ECTO} -Fab 77.

1582

A) 2D Classification and simplified schematic of NS EM heating experiment with the F_{ECTO} -Fab 77 complex. The F_{ECTO} -Fab 77 complex was heated for 5 min at 50 °C, followed by rapid cooling on ice and preparation of NS EM grids. 2D classification analysis revealed heterogeneous conformations of the F_{ECTO} -Fab 77 complex.

1584

1586


B) A comparison between the 2D classes obtained from cryo-EM and NS EM experiments shows a good agreement between the two techniques in terms of particle morphology and conformation.

1588

C, D) 5-min, 50° C heat-treated controls for Fab 77 and F_{ECTO} .

E) Unheated control for the F_{ECTO} -Fab 77 complex.

1590 F, G, H, I) Time-resolved thermal analysis of F_{ECTO}-Fab 77. The most representative or the sole class
1592 obtained during the 2D classification round is shown. As indicated in Fig S11A, all datasets were
1594 processed using identical parameters regarding micrograph pre-processing, particle picking, and 2D
1596 classification. The states that were obtained are color-coded: violet: Fab 77, green: F_{ECTO}/F_{ECTO}-Fab 77
in pre-fusion conformation, slate blue: F_{ECTO} in post-fusion conformation, orange: relaxed/open state
of F_{ECTO}-Fab 77, red: Fab-stabilized F_{ECTO} fragment.




1598 **Figure S11. Processing workflow and statistics for the Fab 77- F_{ECTO} fragment and refolding**
 1600 **intermediates.**

1600 A) General processing workflow for NS EM datasets.

1602 B) Cryo-EM processing workflow for the Fab 77- F_{ECTO} fragment.

1602 C, D, E, F) Local resolution, local resolution histogram, FSC, and angular distribution of the final Fab 77- F_{ECTO} fragment map.

1604 G) $C\alpha$ RMSD between F_{ECTO} -Fab 77 structure and Fab 77-stabilized F_{ECTO} fragment shows minor changes
 1606 of the F_{ECTO} epitope upon glycoprotein separation. The intensifying red gradient indicates an increase
 in $C\alpha$ RMSD, with arrows pinpointing F and Fab regions.



1608 **Figure S12. Distinguishing three main epitopes among 12 antibodies that target the paramyxovirus F protein.**

1610 A) Apex binding antibodies (Fab PIA174: 6MJZ, Fab 12B2: 7KI4, Fab66: 6T3F, Fab 4H3: 7UOP, Fab 3x1: 8DG8, Fab 2D3: 7UP9) recognize the top part of domain III and F2.

1612 B) Face binding antibodies (Fab 1A9: 7UPK, Fab 5B3: 6TYS, Fab 1F5: 7KI6, Fab 1H8: 7UPA) mainly
target domain I and the lower part of domain III.

1614 C) Base binding antibodies (Fab 2B12: 7UPD, Fab 1H1: 7UPB, Fab 77: this study) primarily bind domain
1616 II, the bottom of domain I and the linker region between domain II and HRC. Interestingly, Fab 1H1
also recognizes the post-fusion conformation of Nipah F.

D) Approach angles of antibodies included in A-C. Each axis was determined based on the long dimension
1618 of a whole Fab structure fitting into the available Fab fragment. Axes are colored based on the antibody
colors from A-E) Summary table with all the antibodies discussed and their epitope and corresponding
1620 viral targets. The abbreviations are as follows: hPIV: Human Parainfluenza Virus, NiV: Nipah Virus, HeV:
Hendra Virus, MeV: Measles Virus.

Table S1. Model and map statistics.

Model PDB ID EMDB ID Composition (#)	F _{ECTO} -Fab 77 8UT2 EMD-42527	F _{ECTO} post-fusion 8UTF EMD-42539	F _{ECTO} -(FIP-HRC4) ₂ -PEG11 8UUQ EMD-42595	F _{ECTO} 8UUP EMD-42593	Fab 77-F _{ECTO} fragment 9AT8 EMD-43827 / EMD-43828
Chains	16	11	13	10	5
Atoms	16159 (Hydrogens: 0)	9894 (Hydrogens: 0)	10768 (Hydrogens: 0)	10729 (Hydrogens: 0)	3088 (Hydrogens: 0)
Residues	Protein: 2037	Protein: 1256	Protein: 1357	Protein: 1357 Nucleotide: 0	Protein: 396 Nucleotide: 0
Water	229	134	33	105	0
Ligands	BMA: 6 NAG: 15	NAG: 9	LIG: 3 NAG: 15 BMA: 6 MAN: 4	BMA: 6 NAG: 15	NAG: 1
Model statistics					
Bonds (RMSD)					
Length (Å) (# > 4sigma)	0.003 (0)	0.002 (0)	0.006 (0)	0.002 (0)	0.002 (0)
Angles (°) (# > 4sigma)	0.548 (0)	0.525 (0)	0.685 (1)	0.523 (0)	0.535 (0)
MolProbity score	1.55	1.25	1.14	1.12	1.91
Clash score	6.47	4.88	3.53	3.27	9.22
Ramachandran plot (%)					
Outliers	0.20	0.00	0.00	0.00	0.00
Allowed	2.98	1.21	1.71	1.64	6.44
Favored	96.82	98.79	98.29	98.36	93.56
Rama-Z (Ramachandran plot Z-score, RMSD)					
whole (N = 2013)	-0.60 (0.18)	0.25 (0.23)	-0.08 (0.21)	0.44 (0.22)	-1.97 (0.41)
helix (N = 429)	0.23 (0.24)	1.10 (0.23)	0.14 (0.23)	1.01 (0.23)	---
sheet (N = 486)	-0.06 (0.24)	1.23 (0.48)	0.25 (0.35)	0.24 (0.37)	-1.29 (0.47)
loop (N = 1098)	-0.77 (0.18)	-0.86 (0.23)	-0.13 (0.22)	-0.08 (0.22)	-1.36 (0.37)
Rotamer outliers (%)	0.00	0.00	0.00	0.00	0.00
Cbeta outliers (%)	NA	NA	NA	NA	NA
Peptide plane (%)					
Cis proline/general	7.7/0.2	0.0/0.0	0.0/0.0	0.0/0.0	5.9/0.0
Twisted proline/general	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0	0.0/0.0
CaBLAM outliers (%)	1.96	0.79	0.90	0.68	4.74
ADP (B-factors)					
Iso/Aniso (#)	16159/0	9894/0	10768/0	10729/0	3088/0
min/max/mean					
Protein	7.78/145.94/55.27	0.00/196.59/75.85	14.91/124.73/48.03	9.78/127.18/41.02	7.19/116.77/33.72
Ligand	27.94/156.21/78.74	102.93/151.05/126.78	0.20/171.70/57.90	-0.00/104.16/50.63	66.91/66.91/66.91
Water	13.74/72.27/39.79	33.21/102.23/55.55	23.07/53.29/37.59	15.04/47.76/29.70	---
Occupancy					
Mean	1.00	1.00	1.00	1.00	1.00
Data					
Box					
Supplied Resolution (Å)	2.6	2.7	2.3	2.11	3.8
Resolution Estimates (Å)	Masked/(Unmasked)	Masked/(Unmasked)	Masked/(Unmasked)	Masked/(Unmasked)	Masked/(Unmasked)
d FSC (half maps; 0.143) (Å)	2.56	2.72	2.34	2.11	3.6
d model	2.9/(3.0)	3.1/(3.1)	2.6/(2.6)	2.4/(2.5)	3.5/(3.5)
d FSC model (0/0.143/0.5) (Å)	2.5/2.5/2.8/ (2.5/2.6/3.0)	2.6/2.7/3.0/ (2.7/2.7/3.1)	2.2/2.3/2.5/ (2.3/2.3/2.7)	2.1/2.1/2.3/ 2.1/2.2/2.4	2.8/3.4/3.7/ 2.8/3.4/3.7
Map min/max/mean	2.73/3.40/0.03	4.28/6.60/0.04	2.73/4.58/0.03	2.30/3.15/0.00	-7.32/11.44/0.08
Model vs. Data					
CC (mask)	0.81	0.82	0.89	0.72	0.69
CC (box)	0.69	0.67	0.72	0.58	0.62
CC (peaks)	0.67	0.65	0.72	0.58	0.56
CC (volume)	0.79	0.80	0.87	0.71	0.67
Mean CC for ligands	0.65	0.54	0.64	0.68	0.51
Data acquisition					
Microscope / camera	Thermo Titan Krios G3 300kV / Gatan K3 + GIF Bioquantum				
Magnification	130 000 X				
Exposure / total electron exposure	2.5 s / ~50 e/Å ²			2 s / 70 e/Å ²	2.5 s / ~50 e/Å ²
Frames	50				
Defocus range	-0.6-2.5 μm				
Pixel size (raw/final) (Å)	0.66 / 1.056	0.66 / 0.99	0.66 / 0.88	0.66 / 0.92	0.66 / 1.403
Number of micrographs (all/final)	10344 / 7798	6028 / 5420	10716 / 5830	7980 / 7965	10344 / 7798
Number of particles (unique / symmetry expanded)	142852 / 428556	52850 / 158562	100661 / 235003	354182 / 454125	94848 / -
Box size (raw/final) (px)	512 / 320	600 / 400	400 / 300	420/300	340 / 160
Symmetry		Local C1 from symmetry expanded C3			C1

1624

1626 Table S2. mAb 77-F interface statistics per chain.

Interface	Interface area (Å ²)	ΔG (kcal/mol)	Hydrogen bonds	Salt bridges
HC-F1'	466	-2	7	1

HC-F2'	283	-4	4	0
HC-F1''	140	-1.5	2	0
LC-F1''	106	-1.1	2	0
Total	995	-8.6	15	1

1628

Table S3. CRD regions of mAb 77 involved in F binding.

CDR	Residue range	Interactions
CDR H-1	31-36	4
CDR H-2	51-66	3
CDR H-3	99-110	7
CDR L-2	69-75	2

1630

1632

Table S4. Hydrogen bonds and salt bridges between mAb 77 and F at the

1634 HC CDR 3 F1_A Interface

Hydrogen bond	HC residue [atom]	Distance (Å)	F1' residue [atom]
1	TRP 101 [N]	3.08	GLN 383 [OE1]
2	TYR 107 [OH]	2.38	ARG 435 [O]
3	TYR 107 [OH]	3.5	ARG 435 [N]
4	TYR 107 [O]	2.9	ARG 436 [NH1]
5	TYR 105 [O]	2.96	ARG 436 [NH1]
6	ASP 109 [OD1]	2.74	ARG 436 [NH2]

Salt bridge	HC residue [atom]	Distance (Å)	F1' residue [atom]
1	ASP 109 [OD2]	2.97	ARG 436 [NH2]

1636

HC CDR 1 F1_A Interface

Hydrogen bond	HC residue [atom]	Distance (Å)	F1' residue [atom]
7	ASP 32 [OD2]	2.5	GLN 383 [N]
8	TYR 33 [OH]	3.54	GLY 384 [N]

1638

HC CDR 1 F1_B Interface

Hydrogen bond	HC residue [atom]	Distance (Å)	F1'' residue [atom]
13	TYR 27 [OH]	3.12	LEU 123 [O]
14	SER 31 [O]	3.46	VAL 125 [N]

1640

HC CDR 2 F2_A Interface

Hydrogen bond	HC residue [atom]	Distance (Å)	F2' residue [atom]
9	TYR 54 [OH]	3.22	GLY 37 [O]
10	ARG 72 [NH2]*	3	SER 40 [O]

11	THR 55 [OG1]	3.41	TRP 27 [NE1]
12	THR 57 [OG1]	3.75	TRP 27 [NE1]

1642 *not part of CDR-H2

1644 LC CDR 2 F1_A Interface

Hydrogen bond	LC residue [atom]	Distance (Å)	F1" residue [atom]
15	TYR 49 [OH]	3.14	ARG 435 [N]
16	GLN 55 [OE1]	2.99	SER 434 [OG]

Table S5. Residue variants present in the mAb 77 epitope.

Residue Position ^a	Original Residue	Residue Variation	Interaction Type	Total interactions
27	W	-	Sidechain	2
37	G (99.88%)	R (0.12%)	Backbone	1
40	S	-	Sidechain/Backbone	1
123	L	-	Backbone	1
125	V	-	Backbone	1
383	Q	-	Sidechain/Backbone	2
384	G	-	Backbone	1
434	S	-	Sidechain/Backbone	3
435	R	-	Backbone	3
436	R (72.89%)	K (27.11%)	Sidechain	3

1646 ^aVariant residues shown in bold were tested for their effect on mAb 77 binding.

1648

Movies

1650 *Movies SI. A model morph between F_{ECTO} pre-fusion and post-fusion models shows the movement of domains with respect to domain I.*

1652